Tarek I. Hassanein, M.D. · Page 1 . CURRICULUM VITAE . Tarek I. Hassanein, M.D. . Business...

Page 1

CURRICULUM VITAE

Tarek I. Hassanein, M.D.

Business Address:

Email: Date of Birth:

131 Orange Avenue, Suite 101, Coronado CA 92118 Phone: 619-990-1698 [email protected] 07/13/57

EDUCATION:

1975-1976 Alexandria University, Alexandria, Egypt, Pre-Medicine 1976-1982 Alexandria University, Alexandria, Egypt, M.B.,Ch.B with honors 1984-1987 Alexandria University, Alexandria, Egypt, Master of Science/Internal Medicine 1989- ECFMG 1989- FLEX (PA) 1992- American Board of Internal Medicine, Diplomat 1993- American Board of Gastroenterology, Diplomat 2006- American Board of lnternal Medicine, Transplant Hepatology, Diplomat

POST- GRADUATE TRAINING:

1992-1994 University of Pittsburgh, Pittsburgh, PA, Fellow GI/Hepatology 1990-1992 Wayne State University, Detroit, MI, Resident, Internal Medicine, PGY II-III 1988-1990 University of Pittsburgh, Pittsburgh, PA, Research Fellow, GI/Hepatology 1984-1987 Alexandria University, Alexandria, Egypt Resident, Internal Medicine, PGY I-III 1983-1984 Military Service, Cairo, Egypt, Internship, Neonatology and Pediatrics 1982-1983 Alexandria University, Alexandria, Egypt, Internship

CURRENT POSITION:

2009 -

2009 -

2009-

2009-

Medical Director Southern California GI & Liver Centers Director Southern California Research Center Coronado, CA

Professor of Medicine, School of Medicine University of California San Diego San Diego CA

Medical Director Gastroenterology Services & Comprehensive Liver Care Services Sharp Coronado Hospital Coronado, CA

Hassanein, Tarek

Page 2

2014 - Director of Outreach Services for Liver Transplantation University of California San Diego San Diego, CA

2009-2014 Associate Director of Liver Transplantation Scripps Green Hospital, La Jolla, CA

1998-2010 Director of Liver Clinical Trials Center UCSD Medical Center, San Diego, CA

2005-2009 Professor of Clinical Medicine & Surgery School of Medicine, University of California San Diego, San Diego, CA

1997-2009 Medical Director, UCSD Liver Transplantation

2004-2009 Chief of Specialized Liver Cancer Unit Moore’s Cancer Center, UCSD, San Diego, CA

CLINICAL APPOINTMENTS: 2009- Medical Director

Southern California Liver Centers Coronado, CA

2008-2009 Medical Director, UCSD Liver Transplantation Program

Director, Liver Clinical Trials Center University of California San Diego Medical Center, San Diego, CA

1996-2009 Chief of Specialized Liver Cancer Unit

Moore’s Cancer Center, UCSD, San Diego, CA

1997-2008 Chief of Clinical Hepatology Director, UCSD Liver Center Medical Director, UCSD Liver Transplantation Program University of California San Diego Medical Center, San Diego, CA

1995–1997 Chief of Hepatology and Transplant Gastroenterology

Loma Linda University Medical Center, Loma Linda, CA

1994-1995 Assistant Chief of Transplant Medicine

Oklahoma Transplantation Institute Baptist Medical Center of Oklahoma, Oklahoma City, OK

Hassanein, Tarek

Page 3

ACADEMIC APPOINTMENTS: 2009- Professor of Medicine

School of Medicine University of California San Diego, San Diego, CA

2005-2009 Professor of Clinical Medicine and Surgery


1997-2005 Associate Professor of Clinical Medicine and Surgery


1995-1997 Associate Professor of Medicine

School of Medicine Loma Linda University, Loma Linda, CA

1994.1995 Visiting Research Associate

Pittsburgh Transplantation Institute University of Pittsburgh, Pittsburgh, PA

1987–1988 Assistant Lecturer

School of Medicine Alexandria University, Alexandria, Egypt

AWARDS AND HONORS:

2014 American Liver Foundation Achievement Award 2011 United States Senate Certificate of Commendation (Dianne Feinstein) 2011 Certificate of Special Congressional Recognition (Brian P. Bilbray) 2011 Certificate of Special Congressional Recognition (Susan A. Davis) 2011 State of California Senate Certificate of Recognition (Mark Wyland) 2011 ALF Combined Health Agencies Health Hero Award 2009 Fellow, American Gastroenterological Association 2005-2006 Professional Development of Future Physicians Award, UCSD 2000 Life member of the National Registry of Who’s Who in the 2000 edition. 1999 “My Boss is a Patriot” Award, United States Naval Reserves 1998 Fellow of American College of Gastroenterology 1997 Fellow, American College of Physicians 1994 ACG/Astra Merck Group Senior Fellow Award 1990 4th Annual Glaxo Fellow Travel Award 1987.1988 Peace-Fellowship Award, US Agency of International Development 1979.1981 Academic Achievement Award, Alexandria University 1975-1976 Academic Achievement Award, Alexandria University

Hassanein, Tarek

Page 4

CERTIFICATION AND LICENSURE:

Physician License, State of California, #A54452 Physician License, Egypt Physician Assistant Supervisor State of California, #SA30942 American Board of Gastroenterology, Diplomat #146759, 1993-2023 American Board of Internal Medicine, Diplomat #146759, 1992-2022 American Board of Internal Medicine, Diplomat, Transplant Hepatology, 2006-2026 ECFMG #415-413-4, 1989 FLEX (PA) #570713015, 1989

MEMBERSHIPS:

• American Medical Association • American College of Physicians • American College of Gastroenterology • American Gastroenterological Association • American Association of the Study of Liver Disease • European Association for the Study of the Liver • American Society of Transplant Physicians • National Arab American Medical Association • International Liver Transplantation Society • International Gastro-Surgical Club • Gastroenterology Research Group • San Diego County Medical Society • San Diego Gastroenterology Society • American Liver Foundation San Diego Chapter • California Medical Association

EDITORIAL BOARD: • Editorial Board, Liver Transplantation, Past Member • Editorial Board, Hepatology and Gastroenterology, Active Member • Regional Editor, Hepato-Gastroenterology, Past Member • Editorial Board, Digestive Diseases & Sciences, Active Member • Arab Journal of Gastroenterology, International Advisory Board, Active Member • Egyptian Liver Cancer Association, International Advisory Board, Active Member

REVIEWER: • Hepatology • Journal of Hepatology • Gastroenterology • American Journal of Gastroenterology • Digestive Diseases and Sciences • Mayo Clinic Proceedings

Hassanein, Tarek

Page 5

• Journal of Medical Virology • Medical Principles and Practice • Cancer Investigation • Oncology • International Neuropsychological Society • Alimentary Pharmacology & Therapeutics

ADVISORY BOARDS/DEVELOPMENT MEETINGS:

1. Faculty 2000 HCV Advisory Board, Roche Laboratories, September 5, 1997. 2. Roferon-A Hepatitis C Advisory Board, Roche Laboratories, January 21, 1998. 3. 1998 Ribavirin Investigators Meeting, Schering, January 29, 1998. 4. Management of Interferon Treatment Failures in Chronic Hepatitis C Roundtable

Meeting, Postgraduate Institute for Medicine, March 2, 1998. 5. VPA-985 Investigator Meeting, Wyeth-Ayerst, April 6, 1998. 6. Clinician's Companion II Development Meeting on Hepatitis C, Projects in Knowledge,

June 18, 1998. 7. Roundtable Workshop, Management of Interferon Treatment Failures in Chronic

Hepatitis C, Dallas TX, 1998. 8. 1999 Rebetron Investigators Meeting, Schering, February 4, 1999. 9. Pegasys Advisory Board, Roche Laboratories, March 19, 1999. 10. Clinician's Companion III Development Meeting on Hepatitis C, June 19, 1999. 11. California Hepatitis C Coalition, 2000 12. Task Force to Develop Strategic Plan for California for Hepatitis C, 2000. 13. SHINE, February, 2000. 14. 2nd Annual Pegasys Global Investigators Event, London, Roche Laboratories, May 3-6,

2001. 15. GI/Hepatology Advisory Board, Beverly Hills CA, November 20, 2001. 16. Pegasys National Advisory Board, Roche Laboratories, March 1-3, 2002. 17. Pegasys Advisory Board, Roche Laboratories, April 6, 2002. 18. Ortho Biotech HCV Regional Ad Board, Symbiotix, August 9, 2002. 19. Consultant, Schering, September 1, 2002-August 31, 2003. 20. GI/Hepatology Regional Advisory Board, Roche Laboratories, March 7-9, 2003. 21. Hepatitis C Advisory Board Meeting, Amgen, Santa Monica CA, November 21-22,2003. 22. Outcomes Research Advisory Board, Roche Laboratories, November 23-24, 2003. 23. Steering Committee, Clinical Research Network in Nonalcoholic Steatohepatitis

(NASH/CRN), January 29-30, 2004. 24. AGHC-002 Investigators Meeting, Intermune, March 12-14, 2004. 25. HCV Joint MD/NP/PA Regional Advisory Board, April 23, 2004. 26. Amgen Hepatitis C Advisory Board, Marina Del Rey CA, May 1, 2004. 27. Steering Committee, Nonalcoholic Steatohepatitis Clinical Research Network (NASH

CRN), Intermune, June 2004. 28. Hepatology National Advisory Board, Intermune, June 4-6, 2004. 29. Schering Corporation Advisory Board, Schering, July 15-16, 2004. 30. PEGASYS National Advisory Board, Roche Laboratories, August, 2004. 31. Roche Laboratories Advisory Board, September 2004. 32. Intermune Steering Committee, December 2004. 33. AMA CME Hepatitis C Advisory Board, 2005.

Hassanein, Tarek

Page 6

34. InterMune Hepatology Regional Advisory Board, April, 2005. 35. Prospectives in Hepatitis C Outcomes: An Educational Network for Improving Options

in Treatment Failures (PHOENIX) Advisory Board. 36. Member, Scientific Interest Group, “NeuroAIDS Therapeutics & Comorbidities: Clinical

& Laboratory Markers” for the Neuromedical Core of the HIV Neurobehavioral Research Center (HNRC), UCSD Medical School.

37. PEGASYS Speakers Bureau Training, May, 2005. 38. Viramidine Advisory Board, May 2006. 39. Schering Fatigue Advisory Board, June 2006. 40. Roche Counter-IDEAL Advisory Board, August 2006. 41. Valeant Pharmaceuticals Infergen Advisory Board, September 2006. 42. Gilead Sciences HBV National Advisory Board, September 2006. 43. Hepsera Regional Consulting Meeting, Dana Point CA, September 2006. 44. NIDDK Acute Liver Failure Meeting, Bethesda MD, December 2006. 45. 2007 CME Programming Meeting, Paradise Valley AZ, March 2007. 46. Conquering Contemporary Challenges: New Hope with Targeted Therapy for

Hepatocellular Carcinoma, CME Innovations ENACH, New York NY, July 2007. 47. “New Management Strategies for HCV Nonresponders and Relapsers”, Author, Online

Interactive Case Programs, Clinical Care Options, September 2007. 48. Chronic Liver Disease Foundation HCV/HBV/HE Content Development Meeting, Dallas

TX, February 2008.

BOOKS AND MEDIA:

1. Hassanein T, Van Thiel DH, Gurakar A. Gut Permeability. In: Update in Intensive Care and Emergency Medicine, Springer-Verlag, Heidelberg (Germany), 1995;128-144

2. Hassanein T, Van Thiel DH. Biochemical abnormalities in liver disease. Bailliere Clinical Gastroenterology 1995;9:679-688.

3. Fagiuoli S, Gurakar A, Hassanein T, Wright HI, Van Thiele DH. Liver resection and transplantation. In: Consultations in Gastroenterology, Snape W(ed.), W.B. Saunders, New York, 1996;828-842.

4. Advisor “Hepatitis C: A Personal Guide To Good Health”, Roybal, B, 1997. 5. Interviewed “Hepatitis What You Need to Know” 1997. 6. Hepatitis C”, News and Views for Primary Care. Taping, 1997.Dateline Interview. April

2001. 7. "Hepatitis C", June 2001. 8. “Safety Alert! Monitor all Liver Disease Patients for Depression, Anxiety”,

Gastroenterology & Endoscopy News, January 2002. 9. San Diego Union Tribune, August 2004. 10. “Blood Purification Systems”, Trauma and Critical Care (in Press). 11. “Tattoos Increase Risk of Contracting Blood-borne Viruses”, North County Times,

November 2005. 12. Hepatitis C Radio Tour in 16 cities, September 2006. 13. “TV Anchor Going Public with Hepatitis C Dangers”, San Diego Union Tribune, October

2006. 14. FACE B Speaker Webcast, October 2006. 15. “New Illness Couldn’t Beat Resilient Rolf”, San Diego Union Tribune, November 2006. 16. Health Matters television interview with Channel 8, San Diego CA, January 2007. 17. “Management of HCV Genotype 2/3 Patients”, HCV CME TV, July 2007. 18. You-tube interview with Stan Miller, January 2008.

Hassanein, Tarek

Page 7

19. Shades of San Diego Community Affairs, Channel 4 Television Interview, March 2009. 20. The Sharp Experience, 2010. 21. El Haya Channel TV, Egypt, January 2012. 22. El Mehwar TV, Egypt, January 2012. 23. Egyptian TV Channel 2, Egypt, January 2012. 24. Logos TV, “Epidemic of Hepatitis C in Egypt”, February 2012. 25. Alameen TV, “Liver Diseases in Middle Eastern Immigrants”, February 2012. 26. American Liver Foundation Interview, San Diego Channel 6, June 2014.

THESIS ADVISOR:

2004 Mahmoud Abdelsattar Abdel Hamid Mahgoub El Tahawy, Doctor Thesis “Beta Blockers versus Band Ligation or Sclerotherapy in Management of Variceal Bleeding”, Liver Institute of Egypt, Minofaya Egypt. 2003 Jennifer Koh, Master of Thesis, Biology Committee “Micropatterned Co-Cultures of

Human Hepatocytes and Stromal Cells: An In Vitro Model of Liver Tissue for Cell- Based Assays”, University of California San Diego, San Diego CA. 2003 Gared Allen PhD. Thesis 1999 Mohamed Salah PhD Thesis 2008 Mahamed Amer PhD Thesis 2008 Fatma Barakat, Master Thesis 2007 Renee Pozza, PhD Thesis 2011 Anna Marie Hefner, PhD Thesis

COMMITTEE AND ADMINISTRATIVE SERVICES:

2012 Representative of Professional Egyptian Syndicates 2012 House of Egypt Medical Committee 2011 AGA International Committee 2011 Salam Fund for Education 2010 Sharp Coronado Hospital Foundation 2009 AASLD Special Interest Group, Acute-on-Chronic Liver Failure 2009 AASLD Special Interest Group, Hepatotoxicity 2005 - 2009 UCSD Cancer Committee 2005 Phoenix Steering Committee 2004 - 2009 UCSD GI Division Research & Faculty Development 2004 - 2009 UCSD Recruitment Committee 2004 - 2009 Transplant Executive Committee, UCSD, San Diego 2004 – 2006 AASLD International Education 2003 Chief of GI Recruitment Committee, UCSD 2003 Liver Transplant Steering Committee, UCSD, San Diego 2003 Center of Excellence, Gastrointestinal Cancer, UCSD Cancer Center 2003 NASH CRN Steering Committee 2002 Hepatitis C Strategic Plan Working Group 2002 LifeSharing Medical Advisory Board 2002 Medical Advisory Board, UNOS, Regional Review Committee 2000 Specialized Cancer Unit, UCSD Cancer Center 2000 International Relations Committee, American College of Gastroenterology 2000 International Liaison Committee, American Gastroenterological Association 2000 Africa-Middle East Regional Advisory Group, American Gastroenterological

Association 2000 Liver and Intra-Abdominal Committee, American Society of Transplantation

Hassanein, Tarek

Page 8

2000-2001 Education Committee, American Association for the Study of Liver Diseases 2000-2001 State of California Hepatitis C Working Group 2000 San Diego Hepatitis Community Consortium 2000 San Diego County Education Task Force 1999-2000 Translational Oncology, UCSD Cancer Center 1997 Clinical Committee, Division of Gastroenterology, UCSD 1997 Liver Patient Selection Committee, UCSD Liver Center 1997 Strategic Planning Committee, UCSD Liver Center 1997 Medical Advisory Board, Lifesharing, Community Organ Donation 1997 Research Committee, Division of Gastroenterology, UCSD 1997 Medical Advisory Board, ALF San Diego 1999 Board of Directors, ALF San Diego 1997-2000 Committee on Extended Studies and Public Services, Academic Senate, UCSD 1999-2000 Hepatitis C Planning Group, VA Medical Center San Diego 1999-2000 Preceptor, Graduate Nursing Education Program, UCSD 1998 Nutrition Committee, UCSD Medical Center 1998 Hepatitis Task Force, Senator Polanco, State of California 1997-1999 Medical Advisory Board, Kern Hepatitis Association 1997-1999 Cancer Committee, UCSD Medical Center 1996-1999 Board of Directors, Cassie’s Friends, A Gift of Life 1996-1999 Chair, Medical Advisory Board, ALF, Inland Empire Chapter

TEACHING ACTIVITIES:

1. “Chronic Acute Hepatitis,” Medicine 401 Clerkship, Veterans Administration Medical Center, La Jolla, CA, July 1997-2008.

2. “ESLD,” Surgery 401 Clerkship, V.A. Medical Center, La Jolla, CA, August 1997

3. “Acute Chronic Hepatitis,” Medicine 401 Clerkship, V.A. Medical Center, La Jolla, CA, November 1997.

4. “Acute Chronic Hepatitis,” Medicine 401 Clerkship, V.A. Medical Center, La Jolla, CA,

Jan. 1998.

5. "Hepatitis C", GIM/G Morning Conference, VAMC, January 1998.

6. “ESLD,” Surgery 401 Clerkship, Veterans Administration Medical Center, La Jolla, CA, Feb. 1998.

7. Medical Management Conference, UCSD Department of Medicine, February 1998.

8. Fellow and Resident Teaching on Hepatology/Transplant Service, UCSD, March 1998.

9. "Interpretation of Liver Injury Tests" GIM/G Morning Conference, VAMC, March 1998.

10. "Biliary Disease", SOM 208, April 1998.

11. Medicine Attending, UCSD, April 1998.

12. “Post-op Liver Transplant Management” SICU nurses, UCSD, May 1998.

Hassanein, Tarek

Page 9

13. “Chronic Hepatitis” Medicine 401 Clerkship, UCSD, May 1998.

14. “ESLD” Surgery 401 Clerkship, UCSD, June 1998.

15. “HIV/HCV Co-Infection” UCSD AIDS Clinical Rounds, June 1998.

16. "Hepatitis A through E, Part 1: The Virus, The Disease" UCSD Liver Center, Inpatient services, July 1998.

17. "HIV/HCV Co-Infection" UC Irvine Grand Rounds, July 1998.

18. "Chronic Hepatitis" Medicine 401 Clerkship, UCSD, July 1998.

19. "Ascites" Internal Medicine Noon Conference, UCSD, August 1998.

20. "ESLD" Surgery 401 Clerkship, UCSD, September 1998

21. "Chronic Hepatitis", Medicine 401 Clerkship, UCSD, October 1998.

22. "Hepatitis Update", Internal Medicine Group, UCSD, October 1998.

23. "Liver Failure in the SICU", SICU, UCSD, October 1998.

24. "End Stage Liver Disease" Surgery 401 Clerkship, UCSD, October 1998.

25. "Hepatitis C Update", Grand Round, UCSD Nurse Practitioner Group, October 1998.

26. "Cirrhosis and Portal Hypertension" Surgery Resident Conference, UCSD, December 1998.

27. "Alcoholic Liver Disease" Internal Medicine Conference, VA Medical Center, January

1999.

28. "Viral Hepatitis" Medicine 401 Clerkship, UCSD, February 1999.

29. "ESLD" Surgery 401 Clerkship, UCSD, March 1999.

30. "Auto immune hepatitis" UCSD Medical Management Conference, March 1999.

31. "Induction vs. combination therapy" GI Research Seminar, April 1999.

32. "Biliary Disease" SOM 208, April 1999.

33. "ESLD" Surgery 401 Clerkship, UCSD, May 1999.

34. "Viral Hepatitis" Medicine 401 Clerkship, UCSD, May 1999.

35. OSCE Course, UCSD, May 1999.

36. “Viral Hepatitis” Medicine 401 Clerkship, UCSD, July 1999.

37. “Hepatitis” Medicine Grand Rounds, VAMC, August 1999.

38. “Split Liver Transplantation” GI Grand Rounds, UCSD, September 1999.

Hassanein, Tarek

Page 10

39. “Ascites”, Medicine Noon Conference, UCSD, October 1999.

40. “Hepatitis C and Liver Transplant Update”, Medical Grand Rounds, VAMC, October 1999

41. Medical Management Conference, Internal Medicine, UCSD, November 1999.

42. “Combination Therapy”, Hepatitis C Support Group, UCSD, November 1999.

43. Student Teaching, MED 496, UCSD SOM, Fall 1999.

44. Student Teaching, MED 299, UCSD SOM, Winter 1999.

45. “FHF”, GI Grand Rounds, UCSD, January 2000.

46. “Viral Hepatitis” Medicine 401 Clerkship, UCSD, January 2000.

47. Introduction to Clinical Medicine 201B, ICM Course, January 2000.

48. “Mechanisms of Hepatic Fibrogenesis” Basic Science Seminar, UCSD, February 2000.

49. “Hepatorenal Syndrome”, Post-graduate Course in Surgery, UCSD, Department of Surgery, February 2000.

50. Student Teaching, MED 467, UCSD SOM, March 2000.

51. “Alcoholic Liver Disease” Basic Science Seminar, UCSD, April 2000.

52. “Fulminant Hepatic Failure” SICU, UCSD Medical Center, April 2000.

53. “Acute Chronic Hepatitis” Medicine 401 Clerkship, UCSD, April 2000

54. “Hepatic Cirrhosis” SOM 208 Human Disease, UCSD, April 2000.

55. Objective Structured Clinical Exam, UCSD, April 2000.

56. Student Teaching, ISP, UCSD SOM, May 2000.

57. “DDW Update” Grand Rounds, Div of GI, June 2000.

58. “A B C’s of Hepatitis: Emphasis on C”, Fallbrook Hospital Grand Rounds, June 2000.

59. “Acute Chronic Hepatitis”, Medicine 401 Clerkship, UCSD, July 2000.

60. “Update on Hepatitis C Treatment”, UCSD Liver Center Hep C Support Group, August 2000.

61. “Acute Liver Failure”, Basic Science Seminar, GI Division, August 2000.

62. “Fulminant Hepatic Failure”, Grand Rounds, Medical College of Georgia, GI Division, September 2000.

63. “New Therapies for Hepatitis C”, Grand Rounds, University of South Carolina, GI

Division, September 2000.

Hassanein, Tarek

Page 11

64. “Ascites”, Medical Residents Lecture, VAMC, September 2000.

65. “Viral Hepatitis” Medicine 401 Clerkship, UCSD, October 2000.

66. “Hepatitis C”, Grand Rounds, Northridge Medical Center, Northridge CA, November 2000.

67. "Viral Hepatitis" Medicine 401 Clerkship, UCSD, January 2001.

68. “Hepatitis in the Dialysis Patient”, UCSD Nephrology Post-graduate Course, February 2001.

69. “Hepatitis and Primary Liver Tumors”, UCSD Post-graduate Assembly in Surgery,

February 2001.

70. Objective Structured Clinical Exam, UCSD, April 2001.

71. “Cirrhosis” SOM 208 Human Disease, UCSD, April 2001.

72. "Hep C," I.M. Grand Rounds, VAMC Feb 2001.

73. "Hep B," I.M. Grand Rounds, VAMC March 2001.

74. "MARS," G.I. Research, UCSD March 2001.

75. "Viral Hepatitis and HCC," Trans Onc., UCSD Cancer Center April 2001.

76. "Viral Hepatitis", Medicine 401 Clerkship, May 2001.

77. "Viral Hepatitis", Medicine 401 Clerkship, July 2001.

78. "Acute Liver Failure", Basic Science Seminar, VAMC, August 2001.

79. “Hepatitis C”, Medicine Rounds, Scripps Memorial Hospital, Chula Vista CA, August 2001.

80. "Update on Research Practices" Liver Conference, UCSD Liver Center, September 2001

81. "Hepatitis C", Family Medicine Grand Rounds, October 2001.

82. "Viral Hepatitis", Medicine 401 Clerkship, October 2001.

83. "Management Techniques of Hepatitis C", Internal Medicine Grand Rounds, Alvarado Medical Center, November 2001.

84. "Drug Induced Liver Disease", Basic Science Seminar, GI, UCSD, January 2002.

85. "HBV" VAMC General Internal Medicine Grand Rounds, January 2002.

86. "Viral Hepatitis", Medicine 401 Clerkship, February 2002.

87. "Bacterial and Parasitic Infection of the Liver", Basic Science Seminar, GI, UCSD, March 2002.

Hassanein, Tarek

Page 12

83. Report on UCSD Liver Center Activities" GI Retreat, UCSD, March 2002.

88. “Cirrhosis” SOM 208 Human Disease, UCSD, April 2002.

89. "Transition of Lab Inventions to the Clinical Setting" Biomedical Group, UCSD, April 2002.

90. "Live Your Life" N.P, R.N., P.A. Speaker Training April 2002.

91. "M.A.R.S Update” Grand Rounds, Div of GI, May 2002

92. "Viral Hepatitis", Medicine 401 Clerkship, June 2002.

93. American Academy of Family Practitioners, November, 2002

94. “Viral Hepatitis”, Medicine 401 Clerkship, March 2003.

95. "Viral Hepatitis", Medicine 401 Clerkship, November 2003

96. “Drug Induced Liver Disease”, Basic Science Seminar, November 2003

97. “Mechanisms of Hepatic Fibrogenesis”, Basic Science Seminar, November 2003

98. "Viral Hepatitis", Medicine 401 Clerkship, February 2004.

99. "Viral Hepatitis", Medicine 401 Clerkship, June 2004.

100. Gilead Sciences Hepatitis B Speakers’ Bureau, June 2004

101. "Viral Hepatitis", Medicine 401 Clerkship, July 2004.

102. “Human Disease”, UCSD, School of Medicine, July 2004

103. “Emerging Advances in HCV Management”: A PEGASYS Educational Program, Tucson AZ, November 2004.

104. “Hepatitis C Clinical Practice: Present & Future”, San Diego CA, November 2004.

105. “Hemostatis Grand Rounds: Excessive Bleeding in Medical and Surgical Cases, San Diego CA, January 2005.

106. “Organ Physiology” UCSD School of Medicine, March 2005

107. Grand Rounds, Palomar Medical Center, Escondido CA, May 2005.

108. “Acute & Chronic Hepatitis”, GI Core Lecture Series, June 2005.

109. Acute and Chronic Hepatitis” Medicine 401 Clerkship, UCSD, July 2005.

110. “Extra Corporeal Albumin Dialysis (ECAD): A New Approach to Liver Disease”, UCSD Department of Medicine Grand Rounds, San Diego CA, August 2005.

111. “Extra Corporeal Albumin Dialysis (ECAD): A New Approach to Liver Disease”, UCLA

Hassanein, Tarek

Page 13

Department of Medicine Grand Rounds, Los Angeles CA, August 2005.

112. “Hepatitis C”, Grand Rounds, Torrance Memorial Medical Center, Torrance CA, August 2006.

113. “Liver Failure/Liver Dialysis”, Multiorgan Dysfunction Syndrome, Sharp Chula Vista

Medical Center, January 2014.

INVITED LECTURES:

1. “Nutritional therapy for alcoholic hepatitis,” Nutrition Support Service, University of Pittsburgh Medical Center, March 1993.

2. “Emerging treatment for viral hepatitis,” GI Medical-Surgical Conference, University

Health Science Center, Portland OR, April 1994.

3. “Gut Permeability,” First International Symposium on Applied Physiology of the Peripheral Circulation, Barcelona, Spain, September 1994.

4. 4th International Congress of Therapeutic Drug monitoring and Clinical Toxicology,

Vienna, Austria, September 1995.

5. International Workshop on “Epidemiology, Diagnosis and Management of Hepatitis C Infection,” Medical Research Institute, University of Alexandria, Egypt, October 1995.

6. “Conventional Medical and Surgical Management of Fulminant Hepatic Failure,”

International Conference for Apheresis, Kyoto, Japan, April 1996.

7. “Update on Small Bowel Transplantation,” University of St. Louis, St. Louis MO, February 1996.

8. “Update on Hepatitis C,” The Liver Institute, Menofyia, Egypt, March 1996.

9. "Organ Transplants: Complications and Management" US Family Care Medical Center Education Program, February 1997.

10. "Update on Hepatitis", 20th Annual San Diego Postgraduate Assemble in Surgery,

February 1997.

11. “Risk and Management of Hepatitis” Dialysis and Transplant Management, April 1997.

12. “New Treatment in Hepatitis” Dialysis and Transplant Management, April 1997.

13. “Liver Transplant Who and When,” Basic Science Seminar, UCSD, La Jolla CA, July 1997.

14. “New Therapies for HCV,” Veterans Administration Medical Center, La Jolla CA,

August 1997.

15. “Management of Viral Hepatitis,” Alvarado Medical Center, San Diego CA, September 1997.

16. “Update on Liver Transplantation” Palomar Hospital, Escondido CA, October 1997.

Hassanein, Tarek

Page 14

17. “What’s New in Liver Disease,” Scripps Hospital, La Jolla CA, October 1997.

18. “Hepatitis C,” GI and Hep Update, La Jolla CA, November 1997.

19. “Hepatitis B and C,” SD Family Health, San Diego CA, January 1998.

20. “Hepatitis C, the Silent Killer,” UCSD Medical Center, San Diego CA, January 1998.

21. “Hepatitis C,” Veterans Administration Medical Center, La Jolla CA, January 1998.

22. "Hepatitis: Its diagnosis and current treatments", 23rd Annual Postgraduate course Topics and Advances in Internal Medicine, February 1998.

23. “Hepatitis Therapy,” Canji, La Jolla CA, February 1998.

24. “Hepatitis Dx/Tx,” La Jolla CA, February 1998.

25. “Diagnosis of Hepatitis,” Scripps Hospital, Chula Vista CA, February 1998.

26. “Case Presentation,” UCSD Medical Center, San Diego CA, February 1998.

27. “Fulminant Hepatic Failure,” Veterans Administration Medical Center, La Jolla CA, March 1998.

28. “GI Bleeding Banding vs Sclerotherapy,” SCSGNA Long Beach CA, March 1998.

29. “Interpretation of Liver Injury Tests,” Veterans Administration Medical Center, La Jolla CA, March 1998.

30. “Hepatitis C, the Silent Killer,” ALF San Diego North County, Escondido CA, March

1998.

31. “Hepatitis B & C,” Center for Health, Poway CA, March, 1998.

32. “HCV/HIV,” Navy Hospital, April 1998.

33. “Interpretation of Liver Enzyme Values,” CC of Nurse Practitioners, Redlands CA, April 1998.

34. “Hepatitis B and C Treatment,” Yuma Medical Center, Yuma AZ, April 1998.

35. “Biliary Disease,” UCSD, La Jolla CA, April 1998.

36. “Hepatitis and Renal Failure” Dialysis and Transplant Management, April 1998.

37. “Viral Hepatitis Update” Rational Therapeutics Annual Seminar, Anaheim CA, June 1998.

38. “Lamivudine in Treatment of Hepatitis B in the Transplant Patient” Egyptian Society of

Tropical Medicine, Infectious and Parasitic Diseases Annual Congress, June 1998.

39. “FK-506 Immunosuppression and its Management” Egyptian Society of Tropical Medicine, Infectious and Parasitic Diseases Annual Congress, June 1998.

Hassanein, Tarek

Page 15

40. “Lamivudine in Treatment of Hepatitis B” Egyptian Society of Tropical Medicine, Infectious and Parasitic Diseases Annual Congress, June 1998.

41. “New Protocol for DT Artificial Liver” Egyptian Society of Tropical Medicine,

Infectious and Parasitic Diseases Annual Congress, June 1998.

42. “Liver Transplant Update” Misr International Hospital, Egypt, June 1998.

43. “Hepatitis ABC 1998” Family Medicine Update 1998, San Diego CA, June 1998.

44. “Hepatitis C Research and Treatment: What you should know about your own treatment” Kern Hepatitis Association, Bakersfield CA, June 1998.

45. “Hepatitis C: What's New and in the News in 98” Kern Hepatitis Association,

Bakersfield CA, June 1998.

46. "Clinical Interventions for HCV" HCV Global Foundation 2nd International HCV Conference, Oakland CA, August 1998.

47. "Post-op Liver Transplant Living" ALF, Inland Empire Chapter, September 1998.

48. "HIV/HCV Co-Infection", Inland Aids Project, November 1998.

49. "Viral Hepatitis Update" 1998 UCSD Gastroenterology Hepatology Update, November 1998.

50. "Hepatitis Overview", Kern Hepatitis Association, Bakersfield CA, November 1998.

51. "Hepatitis B and C an Overview", Hepatitis Community Forum, ALF Inland Empire, November 1998.

52. "Induction vs. Combination Therapy" Washington University, St. Louis MO, December

1998.

53. "Liver Failure", 22nd Annual San Diego Postgraduate Assembly in Surgery, UCSD, February 1999.

54. "Hepatitis C", 24th Annual Topics and Advances in Internal Medicine, UCSD, February

1999.

55. "Hepatitis C", UCSD Liver Center Support Group, March 1999.

56. "Update on Hepatitis C", UCSD Transplant Support Group, April 1999.

57. "Hepatitis Debate", Pacific Aids Education and Training Center, April 1999.

58. "Hepatitis", ESRD Management Conference, April 1999.

59. “Current Status of Liver Transplantation”, Orange County Hepatitis C Support Group, May 1999.

Hassanein, Tarek

Page 16

60. “Hepatitis A, B, and C for Healthcare Professionals”, Naval Reserve, Naval Medical Center San Diego, September 1999.

61. “New Approaches in the Treatment of HCV”, Hepatitis C Y2K, UCSD, September 1999.

62. “Special Considerations in Patient Management”, Recent Advances in the Treatment of Hepatitis C, Chicago IL October 1999.

63. “Current Hepatitis C Issues”, ALF, San Diego CA, October 1999.

64. “Viral Hepatitis”, 5th Annual Management of Common Gastrointestinal and Liver Diseases, UCSD, November 1999.

65. “ESLD: Pathophysiology and Management Strategies”, Nephrology for the Consultant,

San Diego CA, February 2000.

66. “Management of Liver Failure: New Directions” Topics and Advances in Internal Medicine, San Diego CA, February 2000.

67. “Management of Biliary Obstruction” Clinical Symposium, Topics and Advances in

Internal Medicine, San Diego CA, February 2000.

68. “What is Hepatitis C?”, Azusa Pacific University, Azusa CA, February 2000.

69. “Hepatic Failure”, 5th International Conference on CRRT, San Diego CA, March 2000.

70. “Hepatitis C Standard Therapies”, Hepatology for the Primary Care Provider, April 2000.

71. “HCV Therapies in the Year 2000”, Alexandria Armed Forces Hospital, April 2000.

72. “An Update on Liver Transplantation”, Alexandria Armed Forces Hospital, April 2000.

73. “Clinical issues in Hepatitis C’, Pinnacle Communications, Beverly Hills CA, April 2000.

74. “Hepatitis C”, Oasis Independent Physician Association, Palm Springs CA, May 2000.

75. “Natural History of Hepatitis C” Innovations in the Management of Hepatitis C, Tim Rice and Associates, Beverly Hills CA, May 2000.

76. “Current Strategies for the Diagnosis and Treatment of Hepatitis C”, Innovations in the

Management of Hepatitis C, Tim Rice and Associates, Beverly Hills CA, May 2000.

77. “Side Effects Management”, Innovations in the Management of Hepatitis C, Tim Rice and Associates, Beverly Hills CA, May 2000.

78. “HIV and HCV” Hepatitis on the Front Line, UCI, Irvine CA, May 2000.

79. “Role of the PCC in the Diagnosis and Treatment of Hepatitis C”, Hepatitis Education Initiative, June 2000.

Hassanein, Tarek

Page 17

80. “Diagnosis and Standard Therapy of Hepatitis C”, Hepatitis C Symposium, UCSD Liver Center, June 2000.

81. “Liver Update”, Post DDW Conference, San Diego, CA, July 2000.

82. “Treating Hepatitis C”, Solutions for a Critical Need, Newport Beach CA, July 2000.

83. “Fulminant Liver Support and New Management”, Critical Care Summer Session, July 2000.

84. “Natural History of Hepatitis C and Current Strategies for the Management of Hepatitis”,

Hepatitis Treatment Advocacy, August 2000.

85. “Hepatitis A, B, C”, Hemophilia Council of California, San Diego CA, August 2000.

86. “HIV/HCV Co-Infection”, Department of Health Services, Office of AIDS and Early Intervention Program, State of California, August 2000.

87. “Cholestasis”, International Symposium on Albumin Dialysis in Liver Disease,

University of Rostock, Germany, September 2000.

88. “Clinical Issues in Hepatitis C”, Pinnacle Communications, Marina Del Rey CA, September 2000.

89. “Update on Hepatitis C”, American Liver Foundation Patient Support Group, September

2000.

90. “Hepatitis C”, Medical College of Georgia, GI Division, September 2000.

91. “Treating Hepatitis C” Emory University, September 2000.

92. “Overview of Hepatitis C”, Boron, Las Vegas, October 2000.

93. “Innovations in the Management of Hepatitis C”, Symbiotix, Santa Monica CA, October 2000.

94. “Hepatitis Treatment”, American Liver Foundation Public Forum, San Diego CA,

October 2000.

95. “Diagnosis and Management of Hepatitis C”, Current Trends in Women’s Health, San Diego CA, November 2000.

96. “Treatment Strategies in Managing HCV”, BLP, Eugene OR, November 2000.

97. “Treatment Strategies in Managing HCV”, BLP, Holtville CA, November 2000.

98. “Special Considerations in Patient Management” Promeda, Beverly Hills CA, November 2000.

Hassanein, Tarek

Page 18

99. “AASLD Medical Update”, ALT Staff Leadership Meeting, San Diego CA, December 2000.

100. “Hepatitis: Diagnosis, Treatment and Prevention”, RCH Foundation, December 2000.

101. “Hepatitis B/C”, UCSD Student Health Services, January 2001.

102. “Treatment Strategies in Managing Chronic HCV: Emerging Data on Pegylated Interferons”, Rush-Presbyterian-St. Luke's Medical Center CME, San Diego CA, February 2001.

103. “Management of Decompensated Liver Disease: Detoxification Systems” Sixth

International Conference on CRRT, San Diego CA, March 2001.

104. “The Role of the General Internist in Managing Hepatitis C: New Concepts” Conference: Topics and Advances in Internal Medicine, UCSD, San Diego CA, March 2001.

105. “HCV Treatment Update”, ALF Support Group, March 2001.

106. “Post-Operative Care of Liver Transplant Patients”, The African Middle East Association of Gastroenterology, (AMAGE Congress), Cairo, Egypt, April 2001.

107. “HBV Update”, The African Middle East Association of Gastroenterology, (AMAGE

Congress), Cairo, Egypt, April 2001.

108. “New Modalities in the Management of Liver Failure”, The African Middle East Association of Gastroenterology, (AMAGE Congress), Cairo, Egypt, April 2001.

109. “Novel Therapies of Hepatitis B Infection”, The African Middle East Association of

Gastroenterology, (AMAGE Congress), Cairo, Egypt, April 2001.

110. “Hep C”, Alexandria University Department of Medicine, April 2001.

111. “FHF”, Alexandria University Department. of Medicine, April 2001.

112. “Viral Hepatitis: Prevention and Clinical Care”, San Diego Hepatitis Community Consortium, San Diego CA, April 2001.

113. “Albumin Dialysis”, UCSD Liver Center, San Diego CA, May 2001.

114. “Life Support Systems - The MARS System”, SCTI Research Foundation Yearly Update on ESRD & Kidney Pancreas Transplant Management, May 2001.

115. “Managing Chronic HCV: Emerging Data on Pegylated Interferons”, Rush-Presbyterian-

St. Luke's Medical Center, Irving Texas, May 2001.

116. “Achieving Optimum Outcomes: Customizing Treatment for Patients with HCV Infection”, Educational Initiative in Gastroenterology, Newport Beach CA, May 2001.

Hassanein, Tarek

Page 19

117. “Hepatic Encephalopathy-Impact of MARS Treatment”, 3rd International Symposium on Albumin Dialysis in Liver Disease, Rostock, Germany, September 2001.

118. “HCV/HIV Co-Infection”, New Horizons in Hepatology, UCSD Liver Center, San

Diego, CA, September 2001.

119. “Liver Support Systems in Practice”, New Horizons in Hepatology, UCSD Liver Center, San Diego CA, September 2001.

120. "Day of Remembrance", Lifesharing, November 2001.

121. "HIV/HCV Co-Infection", Comprehensive Care Center, November 2001.

122. “Hepatitis C”, Desert Hospital, Palm Springs CA, November 2001.

123. "HIV and HCV Co-infection", 15th Annual HIV/AIDS on the Front Line Conference, March 2002.

124. "Live Your Life” Management of Hepatitis C, April 2002.

125. “Controversies of the Liver”, USD, San Diego CA, July 2002.

126. “Complications of Liver Disease and Acute Liver Failure”, VA Medical Center, La Jolla CA, August 7, 2002.

127. “HIV/HCV Co-Infection” Ortho Biotech, Los Angeles CA, August 2002.

128. “Albumin Dialysis Liver Disease, International Symposium, Rostock, Germany, September 2002.

129. “Hepatitis & STDs”, San Diego Hepatitis Consortium, San Diego CA, September 2002.

130. “HCV”, Summit Institute of Knowledge, Pasadena CA, September 2002.

131. “Hepatitis A-G”, AAFP Scientific Assembly, La Jolla CA, October, 2002

132. “HIV/HCV CoInfection”, Hoag Hospital, Newport Beach CA, October 2002

133. “Hepatitis C and Organ Transplantation”, Advances in Transplantation, La Jolla CA, October 2002.

134. “HIV/HCV Co-Infection”, American Liver Foundation, San Diego CA, October 2002.

135. “Esophageal Varices”, UCSD, San Diego CA, November 2002.

136. “HIV/HCV Co-Infection”, National Minority Aids Council Regional Conference, San Diego CA, November 2002.

137. “Maximizing Treatment Outcomes for Patients with Hepatitis C”, AdvanceMed,

Lubbock TX, February 2003.

Hassanein, Tarek

Page 20

138. “HIV and HCV Co-Infection”, Department of Public Health Services Office of Aids and Early Intervention Program, State of California, Anaheim, CA, February 2003.

139. “Hepatitis and Hepato-Cellular Carcinoma”, Assembly in Surgery, UCSD, San Diego,

CA, February 2003.

140. “New Therapy in the Management of Chronic Hepatitis C”, Pegasys Education Program, Las Vegas NV, February 2003.

141. “Emerging Advances of HCV Management”, Pegasys Education Program, Tucson AZ,

April 2003.

142. “Emerging Advances of HCV Management”, Pegasys Education Program, Amarillo TX, April 2003.

143. "Hepatocellular Carcinoma and Liver Transplantation", Health Professionals Educational

Seminar, Hepatitis B Prevention Project, San Diego CA, June 2003.

144. “Emerging Advances of HCV Management”, Pegasys Education Program, Greenwood Village CO, September 2003.

145. “Current Treatment of Hepatitis”, ESRD Kidney/Pancreas Transplant Management

Conference, Ontario CA, October 2003.

146. “Management of End Stage Liver Disease”: ESRD Kidney/Pancreas Transplant Management Conference, Ontario CA, October 2003.

147. “Viral Hepatitis: Prevention, Management Future Perspective”, American Liver

Foundation STD/Hepatitis Prevention Program, County of San Diego, San Diego Hepatitis Community Consortium, October 2003.

148. “Management of HCV Infection in Patients Who Are Nonresponders to Previous

Therapy”, Boston MA, October 2003.

149. “Hepatitis C”, El Centro CA, January 2004

150. “Hepatitis C in the Patient with ESRD”, San Diego CA, January 2004.

151. “Treatment of Hepatitis C”, First Annual Postgraduate Course, Cairo, Egypt, February, 2004.

152. “The Hepatologist’s View”, 27th Annual San Diego Postgraduate Assembly in Surgery,

February 2004.

153. “Hepatitis B, When and How to Treat”, Topics and Advances in Internal Medicine Postgraduate Course, San Diego CA, February 2004.

154. “Hepatic Failure”, 9th International Conference On Continuous Renal Replacement

therapies, San Diego CA, March 2004

Hassanein, Tarek

Page 21

155. “Treatment Options for the HCV Nonresponder”, Intermune, San Diego CA, March 2004.

156. “Treatment Options for the HCV Nonresponder”, Intermune, Las Vegas NV, March

2004.

157. “Medical Aspects of Liver Transplantation,” First Madinah International Symposium on Diseases of the Gastrointestinal Tract, Cairo, Egypt, March 2004

158. “Evaluation and Management of Acute Liver Failure”, Hepatology: State of the Art,

Mayo Clinic-Rochester, San Diego CA, April 2004

159. “HCV/HIV Coinfection”, Pegasys Speakers Bureau, Roche Laboratories, Phoenix AZ, April 2004.

160. “Treatment Options for the HCV Nonresponder,” Intermune, San Diego CA, April 2004

161. Treatment Options for the HCV Nonresponder,” Intermune, EL Paso TX April 2004

162. “Treatment Options For The HCV Nonresponder”, Intermune, San Diego CA, May 2004.

163. “What to do for a Patient with Hepatitis B Infection: A Systematic Approach for Diagnosis and Treatment”, Asian Pacific Health Center, San Diego CA, June 2004.

164. “Treatment Options For The HCV Nonresponder”, Intermune, Dallas TX, Houston TX,

June 2004

165. “Hepatitis B Prevention”, Hepatitis Educational Seminar, San Diego CA, June 2004.

166. “Treatment Options for the HCV Nonresponder”, Hepatology Regional Advisory Board, Boston MA & New York, NY, June 2004

167. “DIRECT Trial Awareness”, Intermune, San Diego CA, June & July 2004.

168. “HCV & HIV Crossroads: Integrating Treatment Strategies in the Coinfected Patient”, Fresno CA, July 2004.

169. “Treatment Options for the HCV Nonresponder,” Intermune, Ashland OR, August 2004.

170. “Treatment Options for the HCV Nonresponder,” Intermune, Chicago IL August 2004.

171. “Treatment Options for the HCV Nonresponder,” Intermune, Santa Rosa CA, August 2004.

172. “HIV & HCV Crossroads: Integrating Treatment Strategies in the Coinfected Patient”,

Austin TX, September 2004.

173. “Hepatic Encephalopathy”, 6th International Symposium on Albumin Dialysis in Liver Disease, Rostock, Germany, September, 2004.

Hassanein, Tarek

Page 22

174. “Hepatitis C Update”, SCSGNA Fall Conference, Pala CA, October 2004.

175. “Treatment Options for the HCV Nonresponder”, Intermune, Anaheim CA, October 2004.

176. “Treatment Options for the HCV Nonresponder”, Intermune, Newport Beach CA,

October 2004.

177. “Treatment Options for the HCV Nonresponder”, Intermune, Riverside CA, October 2004.

178. “Treatment Insights: Advances in the Management of Chronic Hepatitis B,” San Diego

CA, October 2004.

179. “Navigating the Obstacles to Hepatitis C Management: Keeping the Patient on Course,” Houston TX, October 2004.

180. “The 2ndTime Around: Retreatment Strategies for the Patient with HCV Infection,”

Education Initiative in Gastroenterology, Boston MA, October 2004.

181. “Hepatitis C”, Infectious Disease Seminar, San Bernardino CA, November 2004.

182. “Treatment Options for the HCV Nonresponder”, Intermune, Pico Rivera CA, November 2004.

183. “MARS, a New Technology for Supporting Liver Failure”, San Diego CA, November

2004.

184. “Treatment Options for the HCV Nonresponder,”, Intermune, Beverly Hills CA, November 2004.

185. Treatment Options for the HCV Nonresponder,”, Intermune, Tucson AZ November

2004.

186. “Hepatitis B The Silent Killer,” Phoenix AZ, November 2004.

187. “DIRECT Trial Awareness,” Intermune, Downey CA, November 2004.

188. “Treatment Options for the HCV Nonresponder,” Intermune, Nichols Hills OK, December 2004.

189. “Treatment Options for the HCV Nonresponder”, Intermune, Hemet CA, January 2005.

190. “Emerging Advances in HCV Management”: A PEGASYS Educational Program, Hershey PA, December 2004

191. “Treatment Options for the Nonresponder,” Intermune, Chapel Hill NC, December 2004.

192. Treatment Options for the Nonresponder,” Intermune, Sacramento CA December 2004.

Hassanein, Tarek

Page 23

193. Treatment Options for the Nonresponder,” Intermune, San Diego CA December 2004.

194. “Treatment Options for the HCV Nonresponder”, Infergen, Las Vegas NV, January 2005.

195. “Approaches to Managing & Treating Chronic Hepatitis B,” San Diego CA, February 2005.

196. “Emerging Advances in HCV Management”, Post AASLD, Roche, Hemet CA, February

2005.

197. “DIRECT Trial Awareness” Intermune, San Diego CA, February 2005

198. “DIRECT Trial Awareness” Intermune, Riverside CA, February 2005

199. “MARS: A New Technology for Supporting Liver Failure”, 10th International CRRT Conference, San Diego CA, March 2005

200. “Treatment Strategies for the HCV Nonresponder”, Intermune, Irvine CA, March 2005.

201. “DIRECT Trial Awareness”, Intermune, Oklahoma City OK, March 2005.

202. “DIRECT Trial Awareness”, Intermune, El Paso TX, March 2005.

203. “Liver Disease At the Crossroads of Civilization: East Meets West”, Alexandria, Egypt, March 2005.

204. “Retreatment Strategies for the Patient with the HCV Infection”, Projects in Knowledge,

Accreditation Council for Continuing Medical Education (ACCME).

205. “Emerging Advances in HCV/HIV Coinfection: An Evidence Based Approach”, Roche, Tucson AZ, April 2005.

206. “Treatment Strategies for the HCV Nonresponder”, Intermune, San Antonio TX, April

2005.

207. “Treatment Strategies for the HCV Nonresponder”, Intermune, Austin TX, April 2005.

208. “Treatment Strategies for the HCV Nonresponder”, Intermune, Salt Lake City UT, April 2005.

209. “DIRECT Trial Awareness”, Intermune, Tucson AZ, April 2005.

210. “Emerging Advances in HCV/HIV Coinfection”, Roche, Fresno CA, April 2005.

211. “DIRECT Trial Awareness”, Intermune, Augusta GA, April 2005.

212. International Hepatitis B Symposium, Abu Dhabi, UAE, May 2005.

213. “Practical Pathways Towards Improved Management of HCV Treatment Failures”, Chicago IL, May 2005.

Hassanein, Tarek

Page 24

214. “Emerging Advances in HCV/HIV Coinfection: An Evidence Based Approach”, Roche, San Diego CA, May 2005.

215. Treatment Strategies for the NCV Nonresponder, Intermune, La Jolla CA, May 2005.

216. “DIRECT” Trial Awareness”, Intermune, Costa Mesa CA, May, 2005.

217. 12th International Symposium on Hepatic Encephalopathy and Nitrogen Metabolism, Dusseldorf, Germany, June 2005.

218. “Treatment Strategies for the HCV Nonresponder”, Intermune, San Diego CA, June

2005.

219. “Treatment Strategies for the HCV Nonresponder”, Intermune, Portland OR, June 2005.

220. “Treatment Strategies for the HCV Nonresponder”, Intermune, Seattle WA, June 2005.

221. “What You Need to Know About Colon Cancer”, Riverside Community Hospital, Riverside CA, July 2005.

222. “A Clinical Plan for the Hepatitis C Nonresponder and Relapse Patient”, National Nurses

Advisory Council, Hepatitis Foundation International, Orange CA, July 2005.

223. “Improving Treatment of HCV by Community Health Centers”, National Association of Community Health Centers, Denver CO, July 2005.

224. “Co-Infection: Treatment & New Therapies”, American Liver Foundation, Viral

Hepatitis 2005 Community Impact, September 2005.

225. “Evaluating Patients Infected with the Hepatitis B Virus and Selecting Candidates for Antiviral Treatment”, Gastroenterology-Hepatology Impact 2006, Phoenix AZ, January 2006.

226. “Stigma in Chronic Disease”, The 5th California Inter-County Annual Hepatitis C Task

Force Conference, Riverside CA, April 2006.

227. “Treatment Strategies for the HCV Nonresponder”, Valeant, Bethesda MD, April 2006.

228. “Treatment Strategies for the HCV Nonresponder”, Valeant, Baltimore MD, April 2006.

229. “HCV in Special Populations”, Roche, Albuquerque NM, April 2006.

230. “Where do we go from here? Emerging Strategies in the Management of HCV Treatment Nonresponders”, 2nd Annual Hepatitis Center Update in Liver Disease, Austin TX, May 2006.

231. “Overview of Hepatitis B Therapies”, Gilead, Paradise Valley AZ, May 2006.

232. “Treatment Strategies for the HCV Nonresponder”, Valeant, Newport Beach CA, May 2006.

Hassanein, Tarek

Page 25

233. “MARS”, Annual North American Pediatric Renal Transplant Cooperative, Las Vegas NV, May 2006.

234. “Optimizing Treatment in Viral Hepatitis: Advances in Patient Care”, Roche, Phoenix AZ,

June 2006.

235. “HCV”, Roche, Grossmont CA, June 2006.

236. “HCV in Special Populations”, Roche, San Diego CA, June 2006.

237. “Treatment Strategies for the HCV Nonresponder”, Valeant, Chicago IL/ Philadelphia PA/ Worchester MA/ Tulsa OK, June 2006.

238. Home Office Training Program, Valeant, Costa Mesa CA, July 2006.

239. “Optimizing Treatment of Viral Hepatitis: Advances in Patient Care”, Las Vegas NV, August 2006.

240. “HCV Treatment Today: From Evidence to Clinical Practice”, Shanghai China, July 2006.

241. Reach Educational Advances in Chronic HBV”, Gilead, July 2006.

242. “Optimizing Treatment of Viral Hepatitis: Advances in Patient Care”, Roche, July 2006.

243. “Understanding NASH and its Treatment” / “Autoimmune Hepatitis” / “Treatment for Hepatitis B and C”, Central American GI Congress, El Salvador, July 2006.

244. “Chronic Hepatitis B: Baraclude as First-Line Treatment Option in Nucleoside-Naïve

Patients”, Bristol-Myers Squibb, Newport Beach CA, August 2006.

245. Pegasys Live Speaker Program, El Centro CA, September 2006.

246. “Current Approaches to HCV Failures of IFN-based Therapies in HCV Infection”, Beth Israel Hospital, New York, September 2006.

247. “Treatment Strategies for the HCV Nonresponder”, Valeant, La Jolla CA, September 2006.

248. “Diagnosing the Patient; Natural History and Progression of Liver Disease”, NACHC HCV Initiative Symposium, San Diego CA, October 2006.

249. “Treatment Strategies for the HCV Nonresponder”, Orange County Gut Club, Fullerton

CA, November 2006.

250. “New Concepts in the Treatment of Hepatitis C”, Riverside CA, November 2006.

251. “Current Status and Future Direction in the Management of Viral Hepatitis”, Pfizer, November 2006.

252. “Treatment Strategies for the HCV Nonresponder”, Salt Lake City UT, November 2006.

Hassanein, Tarek

Page 26

253. “Clinical Insights of Chronic Liver Disease” Meeting and Teleconference, San Diego CA, December 2006.

254. “Managing Hepatitis C Hot Topics 2006”, Spokane WA, December 2006.

255. “Evaluation Patients Infected with Hepatitis B Virus and Selecting Candidates for Antiviral Treatment”, IMPACT Hepatology-Gastroenterology, Laguna Niguel CA, December 2006.

256. “Simply Speaking HBV: An Expert Educator’s CME Lecture Series”, San Diego CA,

January 2007.

257. “ABCs of Hepatitis A, B and C”, 30th Annual San Diego Postgraduate Assembly in Surgery, San Diego CA, February 2007.

258. “Management of Variceal Hemorrhage from Portal Hypertension”, 30th Annual San Diego

Postgraduate Assembly in Surgery, San Diego CA, February 2007.

259. “Hepatitis C: The Current Epidemic”, 20th International Conference on Antiviral Research, Palm Springs CA, May 2007.

260. “Case Approach to Improving Virologic Response, Early and Sustained”, Mesa AZ,

August 2007.

261. “Case Approach to Improving Virologic Response, Early and Sustained”, Las Vegas NV, August 2007.

262. “Emergency Data in the Management of HBV”, Chronic Liver Disease Foundation, Santa

Ana CA, October 2007.

263. “Case Approach to Improving Virologic Response, Early and Sustained”, San Antonio TX, November 2007.

264. “NASH, Clinical Manifestations and Treatment”, Topics and Advances in Internal

Medicine, San Diego CA, March 2008.

265. Chronic Liver Disease Teleconference Series, CLDF, April 2008.

266. CRRT Meeting, San Diego CA, April 2008.

267. “Liver Support Devices in 2012”, 27th Annual New Treatments in Chronic Liver Disease, San Diego CA, March 2012.

268. “Management of Treatment Failure”, ID Week, October 2012.

269. “Diagnostic Testing, Histology, Cirrhosis and Liver Biopsy”, 28th Annual Treatments in Chronic Liver Disease, March 2013.

Hassanein, Tarek

Page 27

RESEARCH STUDIES:

1. A Phase III, Open-Label Randomized, Multicenter Trial to Determine the Efficacy of Recombinant-Methionyl Interferon Consensus (r-metIFN-Con1) in Patients with Chronic Hepatitis C Virus After Prior Treatment with r-metIFN-con1 or Interferon Alpha 2-b Recombinant. 10/1996

2. An Open Labeled Trial of a Sliding Scale, High-dose of Intron A + Ribavirin for

Treatment of Patients With Interferon-Refractory on Interferon-Relapsed Chronic Hepatitis C. 04/1997

3. An Open Labeled Trial of Intron A + Ribavirin for Treatment of Patients with Interferon-

Refractory or Interferon-Relapsed Chronic Hepatitis C. 04/1997

4. An Open Label Trial of Prolonged, High-dose Interferon Alfa-2a (Roferon A) Therapy in Patients with Chronic Hepatitis C Virus. 05/1997

5. Randomized, Double-Blind, Multicenter Comparison of the Effects and Safety of Three

Dose Levels of VPA-985 and Placebo in the Treatment of Patients with Hyponatremia. 02/1998

6. Intron A+ Ribavirin for Treatment of Patients with Chronic Hepatitis C Not Previously

Treated with Interferon (Sliding Scale). 02/1998

7. Intron A + Ribavirin for Treatment of Patients with Chronic Hepatitis C Not Previously Treated with Interferon. 02/1998

8. An Open Label Study of Neoral as a Primary Immunosuppressant Therapy in Transplant

Patients who are Unable to Maintain Satisfactory Immunosuppression on Program (Tacrolimus). 02/1998

9. A Phase III, Randomized, Multicenter, Efficacy and Safety Study Comparing the

Combination of Pegylated Interferon Alpha-2a and Ribavirin with Rebetron in the Treatment of Patients with Chronic Hepatitis C Infection. 10/1998

10. A Phase II/III Double-Blind Study of the Safety and Antiviral Activity of Ribavirin with

Interferon α-2b compared to Interferon α-2b Alone for the Treatment of Patients with Hepatitis C and Co-Infected with HIV. 12/1998

11. A Double Blind Randomized, Placebo Controlled Study of Adefovir Dipivoxil for the

Treatment of Chronic Hepatitis B. 01/1999

12. The complications of Liver Biopsy in HIV Infected Individuals. 06/1999

13. A Randomized Trials of Sliding Scale Rebetron vs Induction Rebetron in Naïve Patients with Chronic Hepatitis C. 06/1999

Hassanein, Tarek

Page 28

14. A Randomized Trial of High Dose Rebetron vs. Induction/Rebetron in Interferon- Refractory or Interferon-Relapse Patients with Chronic Hepatitis C. 7/1999

15. A Phase III, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study of The

Effects of a Somatostatin Analogue-Lanreotide-As Adjuvant to Endoscopic Band Ligation of Patients with Acute Bleeding From Oesophageal Varices Secondary to Cirrhosis and Portal Hypertension. 08/1999

16. Daily Infergen Therapy for Patients with Chronic Hepatitis C Virus who have Failed

Previous Interferon Treatment. 08/1999

17. High-dose Intron A + Ribavirin for Treatment of Patients with Interferon Refractory of Interferon-Relapsed Chronic Hepatitis C. 08/1999

18. An Open-Label, Randomized, Parallel-Group Study Comparing the Effectiveness of

PROCRIT (Epoetin alfa) Administered Once Weekly Versus Standard of Care in Hepatitis C Patients Treated with Combination Ribavirin/Interferon α-2b. 09/1999

19. A Phase III, Randomized, Multicenter, Efficacy and Safety Study Examining the Effects

of the Duration of Treatment and the Daily Dose of Ribavirin in Patients with Chronic Hepatitis C Virus Infection Treated with the Combination of Pegylated-Interferon α-2a and Ribavirin. 09/1999

20. A Randomized, Open-Label, Multicenter, Efficacy and Safety Study of Pegasys plus

Ribavirin, Pegasys plus Cellcept, Pegasys plus Amantadine, or Pegasys plus Amantadine plus Ribavirin in Patients with Chronic-HCV Infection who Relapsed on Rebetron Therapy. 10/1999

21. Interferon ALFACON-1 (Infergen) for the Treatment of Chronic Hepatitis C In Patients

Coinfected with Human Immunodeficiency Virus. 12/1999

22. A Randomized, Partially-Blinded, Multicenter, Phase II, Study Investigating the Efficacy and Safety of Pegasys and Pegasys with Ribavirin in Treatment of Naïve Patients with Chronic Hepatitis Co-infected with Human Immunodeficiency Virus. 2000

23. A Phase III, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study of the

Effects of a Somatostatin Analogue-Lanreotide-as an Adjuvant to Endoscopic Band Ligation of patients with Acute Bleeding from Esophageal Varices Secondary to Cirrhosis and Portal Hypertension. 2000

24. A Pilot Study of Sliding Scale Rebetron vs. Induction/Rebetron in Naïve Patients with

Chronic Hepatitis. 02/2000

25. A Prospective Controlled Study of the Clinical Efficacy of Albumin Dialysis using the Molecular Adsorbent Recirculating Systems (MARS) for the Treatment of Patients with Hepatic Encephalopathy. 03/2000

Hassanein, Tarek

Page 29

26. A Protocol for Re-Treatment with the Combination of Peginterferon Alfa-2b and Ribavirin for Patients with Chronic Hepatitis C in Original Study NV 15942 who Relapsed Virologically After Completing 24 Weeks of Treatment. 09/2000

27. A Prospective Randoized, Multicener, Open-Label Comparative Safety Study of Pegasys

vs. Pegasys Plus Ribavirin Treatment vs. a Twelve Week Treatment Delay in Patients with Chronic Hepatitis C. 12/2000

28. Emergency Use of the Molecular Adsorbent Recirculated Szystem (MARS) for the

Treatment of One Patient with Cholestasis (post hepatic encephalopathy protocol participation. 01/2001

29. A Phase III Study of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in

Adults with Chronic Hepatitis B Infection who are Positive for Hepatitis B E Antigen. 01/2001

30. Emergency use of additional MARS Treatments for One patient, DW, for Grade III and

IV Encephalopathy. 11/2001.

31. A Prospective, Randomized, Phase II Study, Investigating the Safety and Efficacy of Pegasys + Ribavirin Versus Pegasys + Week 12 Addition of Ribavirin in Patients With HIV/HCV Coinfection: Nonresponders or Relapsers to Interferon Monotherapy or in Combination With Ribavirin. 12/2001

32. Emergency Use of the MARS Protocol for One Patient, G.S., for End Stage Liver

Disease. 2/2002

33. Assessment of Driving Behavior of Patients with End Stage Liver Disease. 09/2002

34. Emergency use of the MARS System for One Patient A.S. 1/2003

35. Neuropsychological Profile of Liver Transplant Candidates. 03/2003

36. Depression, Anxiety, Fatigue, Sleep and Substance Abuse in a Clinical Hepatology Population. 04/2003

37. A Prospective, Open-label Dose Escalation Study Evaluating the Saftey and Efficacy of

Infergen Administration by Continuous Delivery Using a Subcutaneous Pump in Combination with Daily Oral Ribavirin in Patients Infected with Hepatitis C Virus who are Treatment Naïve or Peginterferon-alfa Plus Ribavirin or Interferon-alfa Plus Ribavirin Nonresponders. 06/2003

38. UCSD Adult Hepatology and Liver Transplant Clinic Database. 06/2003

39. Epidemiological Study: A Descriptive Review of the Treatment of HIV/HCV Co-

Infection. 06/2003

Hassanein, Tarek

Page 30

40. A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine in Adults with Compensated Chronic Hepatitis B. 11/2003

41. The Influence of Chronic Liver Disease on Psychosocial Factors Associated with Quality

of Life and Adherence. 11/2003

42. NIH – A National Registry of Subjects with Hepatocellular Carcinoma. 11/2003

43. Safety and Tolerability of Sho-saiko-to (SST) in Patients with Compensated Cirrhosis due to Chronic HCV Infection: A Doublie blinded Phase II Trial. 11/2003

44. Validation of a New Method for Grading Hepatic Encephalopathy. 12/2003

45. NIH - Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH) 2004

46. Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With

Nonalcoholic Steatohepatitis (PIVENS) 2004

47. Review of Patients with HIV and Liver Disease. 2004 – 06/2007

48. A Randomized, Double Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C. 01/2004

49. Phase 2, Randomized, Dose-Ranging, Open-label Study of the Safety and Tolerability of

Consensus Interferon-Alpha (CIFN) plus Interferon Gamma-1b (IFN-γ 1b) with or without Ribavirin (RBV) in the Treatment of Patients with Chronic Hepatitis C who are Non-responders to PEG-IFN-α (2a or 2b) plus RBV. 02/2004

50. The Role of Real Time Depression Screening During HCV Therapy with Interferon.

02/2004

51. The UCSD Liver Center Serum & Tissue Repository of Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD). 02/2004

52. NIH: A Multi-Center Group to Study Acute Liver Failure and The Safety And Efficacy

of N-Acetylcysteine (NAC) in the Treatment of Acute Liver Failure (ALF) Not Caused by Acetaminophen in Adult patients. 03/2004

53. A Prospective, Randomized, Open-label Study Evaluating the Viral Kinetics &

Pharmacokinetics of Pegasys Plus Copegus and PEG-Intron plus Rebetol in Interferon- naïve Patients with Chronic Hepatitis C. 03/2004

54. Evaluation of Acute Variceal Bleeding and Rebleeding Treatments. 04/2004

55. A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose

Levels of Interferon Alfacon-1 (Infergen, CIFN) plus Ribavirin Administered Daily for 48 Weeks versus No-treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa plus Ribavirin Therapy. 05/2004

Hassanein, Tarek

Page 31

56. A Randomized, Double Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. 05/2004

57. Sampling Variations in Liver Biopsies. 08/2004

58. A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Intravenous

Terlipressen in Patients with Hepatorenal Syndrome Type 1

59. A Prospective, Multicenter, Open-label, Comparative Efficacy Study of Pegasys® Plus Copegus® in Treatment Naïve Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naïve Non-Latino Caucasian Patients with Chronic Hepatitis C Genotype 1. 11/2004

60. Psychiatric Symptoms and PPI in HCV Patients. 03/2005

61. A Phase 3 Randomized, Open-label Study of the Safety and Efficacy of Two Dose Levels

of Daily Interferon Alfacon-1 plus Ribavirin in Hepatitis C Infected Patients Who Failed to Achieve Virologic Response After {Previous Pegylated Interferon Alfa plus Ribavirin Therapy and during at Least 24 Weeks of No Treatment in IRHC-001. 04/2005

62. A randomized, double-blind study of GT267-004 versus Vancomycin and GT267-004

versus Metronidazole in patients with C Difficile-associated diarrhea. 05/2005

63. Psychiatric Symptoms and the Hypothalamic-Pituitary-Adrenal Axis in Hepatitis C Patients. 05/2005

64. NIH –NeuroAIDS (NIDA): Effects of Methamphetamine and HCV 09/2005

65. A Phase I Prospective, Longitudinal Feasibility Trial of Safety, Tolerance and Efficacy of

SEPET in Patients with Acute Exacerbation of Chronic Liver Disease. 11/2005

66. A Phase 2, Randomized, Active-Controlled Study of the Safety and Efficacy of Ammonul® (Sodium Benzoate) Injection 10%/10% in Patients with Grade III to IV Hepatic Encephalopathy. 12/2005

67. An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously

Treated in Idenix-sponsored Telbivudine Studies. 01/2006

68. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Time-Lagged, Parallel, Multiple-Dose, Escalating-Dose Study to Assess Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Profiles Following Administration of NIM811 in Patients with Viral Hepatitis C Genotype 1 (HCV-1). 02/2006

69. A Multi Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the

Efficacy, Safety and Tolerability of Rifaxamin 550 mg BID for 6 Months in Preventing Hepatic Encephalopathy. 04/2006

Hassanein, Tarek

Page 32

70. Assessment of Hepatic Encephalopathy Scoring Systems. 04/2006

71. A Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-navie Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg. 2006

72. The Early Use of Sanvar® with Endoscopic Treatment for the Control of Acute Variceal

Bleeding Due to Portal Hypertension. 2006

73. Satavaptan in the Prevention of Ascites Recurrence: a double-blind, randomised, parallelgroup comparison of satavaptan at 5 to 10 mg daily versus placebo with concomitant diuretics in patients with recurrent ascites due to cirrhosis of the liver. 2006

74. A Phase II, Randomized, Multicenter, Double-Blinded Study Evaluating the Safety and

Tolerability of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given In Combination with Pegasys With or Without Copegus Versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 Virus Infection. 2006

75. A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and

Efficacy of Pegasys® 180ìg plus Copegus® 1000 or 1200 mg to the Currently Approved Combination of Pegasys® 180ìg plus Copegus® 800 mg in Interferon-naive Patients with Chronic Hepatitis C Genotype 1 Virus Infection Coinfected with Human Immunodeficiency Virus (HIV-1). 2006

76. An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously

Treated in Idenix-Sponsored Telbivudine Studies. 2006 – current

77. A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 Virus Infection. 2007

78. A Phase II, Randomized, Controlled Trial of The Safety And Efficacy Of S-Adenosyl-L-

Methionine Disulphate P-Toluene-Sulfonate (SAMe) In Reducing Serum Alpha- Fetoprotein (AFP) In Patients With Hepatitis C And Moderately Elevated AFP. 2007

79. A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic

use of Maribavir versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants. 2007

80. A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon

Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who

Hassanein, Tarek

Page 33

do not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response. 2007

81. Randomized, Observational Study of Entecavir to Assess Long-term Outcomes

Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection: The REALM Study. 2007

82. Validation of the Acute Physiology & Chronic Health Evaluation (APACHE II) and the

Sepsis-related Organ Failure Assessment (SOFA) in Patients Hospitalized with End Stage Liver Disease (ESLD). 2007

83. UCSD Adult Hepatology and Liver Transplant Clinic Database (Renewal of IRB #

030864X) 2007

84. A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response with a Prior Course of Interferon-Based Therapy. 2007

85. Depression, Anxiety, Fatigue, Sleep, and Substance Abuse in a Clinical Hepatology

Population. 2007

86. A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNƒ¿2a) in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 1. 2007 – current

87. Review of HBV/HIV Co-infected patients. 2008

88. A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48

Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virological Response in Patients with Chronic Hepatitis C, Genotype 2 or 3 who do not Achieve a Rapid Viral Response. 2008

89. A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20

mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH). 2008

90. A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20

mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH). 2008

91. A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon

Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C. 2008

Hassanein, Tarek

Page 34

92. Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naïve HCV-infected patients treated with pegylated interferons. (Prophesys 3). 2008

93. A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of

telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon plus ribavirin treatment. VX950-TiDP24- C216. 2008

94. Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the

Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures. TPL104054 (ELEVATE). 2008.

95. A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to

Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. Protocol # NV20536. 2009

96. An open-label, single-arm, rollover trial of Telapravir in combination with pegylated

interferon alfa 2a and ribavirin for subjects from the control group of the VX950 TiDP24 C216 trial who failed therapy for virologic reasons. 2009.

97. A Phase 2, randomized, double-blind, placebo-controlled, ascending multiple dose trial of

the safety, efficacy, and pharmacokinetics of ANA598 administered with pegylated interferon and ribavirin in treatment naïve genotype 1 patients with chronic Hepatitis C infection. 2009.

98. A Phase 2b, randomized, double-blind, placebo-controlled trial comparing 24 or 48

weeks of GS-9190 in combination with peginterferon alfa-2a and ribavirin, to 48 weeks of peginterferon alfa 2a and ribavirin for the treatment of genotype 1 chronic Hepatitis C virus infection. 2009.

99. Randomized, controlled phase 2a/b study of the efficacy and safety of PEG-rIL-29

administered in combination with ribavirin to treatment-naïve subjects with chronic hepatitis C virus infection. 2009.

100. Exploration of the efficacy of 24-week treatment with PEG-rIL-29 and ribavirin in

subjects with genotype 1 hepatitis C virus who have a genetic polymorphism (CC at rs12979860) associated with a favorable response. 2009.

101. A Phase 2, randomized double-blind, placebo-controlled, study to evaluate the safety and

efficacy of Filibuvir plus pegylated interferon alfa-2a and ribavin in treatment naïve, HCV genotype 1 infected subjects. 2010.

Hassanein, Tarek

Page 35

102. A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Subjects with Hepatic Fibrosis. 2010.

103. A Multi-Center, placebo-controlled, dose ranging study to investigate the safety,

tolerability, pharmacokinetics and pharmacodynamics following oral administration of PSI-7977 in combination with pegylated interferon and ribavirin in treatment-naïve patients with chronic HCV infection genotype 1, and an open label assessment of PSI- 7977 in patients with genotypes 2 or 3. (PROTON) 2010.

104. A Phase 2, double-blind, placebo-controlled study of two doses of EPA-E in patients with

NASH. 2010.

105. A phase 3, randomized, double-bind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI 201335 240 mg for 12 weeks in combination with pegylated interferon-alfa and ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C infection. 2010.

106. A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate

the safety and pharmacokinetics of OCR-002 in patients with stable hepatic cirrhosis. 2010.

107. Randomized, Open-label, Multicenter Study to Evaluate the Antiviral Activity, Safety

and Pharmacokinetics of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267 and/or ABT-333 with and without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-naïve and Null-responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection. 2011.

108. Parallel, open-label, randomized study to evaluate the safety, pharmacokinetics, and

pharmacodynamics of PSI-7977 in combination with BMS-790052 with or without ribavirin in treatment naïve subjects chronically infected with hepatitis C virus genotype 1, 2, or 3. 2011.

109. A Multi-center, open-label, randomized, duration finding study to investigate the safety,

tolerability, pharmacokinetics and pharmacodynamics following oral administration of PSI-7977 in combination with pegylated interferon and ribavirin in treatment-naïve patients with chronic HCV infection genotype 1, 4, 5, or 6. (ATOMIC) 2011.

110. A Multi-center, randomized, placebo-controlled, double-blind study to confirm the

reversal of hepatorenal syndrome Type 1 with Lucassin ® (Terlipressin) IK-4001-HRS- 301. 2011.

111. A Phase 3, multicenter, randomized, active-controlled study to investigate the safety and

efficacy of PSI-7977 and ribavirin for 12 weeks compared to pegylated interferon and ribavirin for 24 weeks in treatment-naïve patients with chronic genotype 2 or 3 HCV infection. (FISSION). 2011.

Hassanein, Tarek

Page 36

112. A Phase 2, randomized, double-blind, placebo-controlled trial evaluating response guided therapy with GS-5885 alone or in combination with GS-9451 with peginterferon alfa 2a and ribavirin in treatment naïve subjects with chronic genotype 1 hepatitis C virus infection. 2011.

113. A Phase 2, randomized, open-label study of GS-5885 administered concomitantly with

GS-9451, Tegobuvir and ribavirin to treatment-naïve subjects with chronic genotype 1 HCV infection. 2011.

114. A Phase 2, randomized, double-blind, placebo-controlled study of GS-5885, GS-9451,

Tegobuvir and ribavirin (RBV) compared with GS-5885, GS-9451 with Tegobuvir or RBV in treatment-experienced subjects with chronic genotype 1a or 1b hepatitis C virus infection. 2011.

115. A Phase 2, randomized, double-blind, placebo-controlled study of GS-5885, GS-9451,

Tegobuvir and ribavirin (RBV) compared with GS-5885, GS-9451 Tegobuvir and ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in interferon ineligible or intolerant subjects with chronic genotype 1a or 1b hepatitis C virus infection. 2011.

116. The QUANTUM Study: An International, multi-center, blinded randomized study to

investigate the safety, tolerability, pharmacokinetics and pharmacodynamics following administration of regimens containing PSI-352938. PSI-7977, and ribavirin in patients with chronic HCV infection. 2011.

117. A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and

Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotypes 1 and 4. 2011.

118. A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group

Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects with Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures. 2011.

119. A randomized, open-label, multicenter study to evaluate the antiviral activity, safety, and

pharmacokinetics of ABT-450 with Ritonavir (ABT-450/r) in combination with ABT- 267 and/or ABT-333 with and without ribavirin for 8, 12 or 24 weeks in treatment naïve and null responder subjects with genotype 1 chronic hepatitis C virus infection. 2012.

120. An open-label, phase 3 study of Telaprevir in combination with peginterferon alfa-2a

(Pegasys®) and ribavirin (Copegus®) in subjects coinfected with genotype 1 hepatitis C virus and human immunodeficiency virus type (HCV/HIV-1) (UNITE). 2012.

121. Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of

Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-Naive Patients and with addition of RO5024048 in Previous Null Responder Patients With Chronic Hepatitis C Genotype 1 or 4 and Compensated Cirrhosis. 2012.

Hassanein, Tarek

Page 37

122. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon. 2012.

123. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to

Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection. 2012.

124. An Open-Label Study of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic

HCV Infection who Participated in Prior Studies Evaluating GS-7977. 2012.

125. A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS- 7977 with Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection. 2012.

126. A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group

Study, with an Open-Label Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects with Chronic Hepatitis C Virus Related Thrombocytopenia who are Potential Candidates for Antiviral Treatment. 2012.

127. Phase 2a Study to Assess the Safety, Pharmacokinetics, and Viral Kinetics of Telaprevir,

VX-222, and Telaprevir Coadministered With VX-222 in Subjects With Chronic Hepatitis C and Moderate to Severe Hepatic Impairment. 2012.

128. A Multicenter, Randomized, Open-label, Phase 2b Study to Evaluate the Efficacy and

Safety of Two Regimens of All-oral Triple Therapy (VX-222 in Combination With Telaprevir [Incivek™] and Ribavirin [Copegus®]) in Treatment-Naïve Subjects With Genotype 1a Chronic Hepatitis C. 2012.

129. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and

Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co- administered with Ribavirin (RBV) in Treatment-Experienced Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II). 2012.

130. Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics,

Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 when administered for 24 or 12 weeks in Treatment-Naïve Subjects Infected with Hepatitis C Virus Genotype 1. 2012.

131. An Open-Label Study of GS-7977 + Ribavirin with or without Peginterferon Alfa-2a in

Subjects with Chronic HCV Infection who Participated in Prior Gilead HCV Studies. 2013.

132. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the

efficacy, safety and pharmacokinetcis of Rifaximin 550 mg in subjects with severe hepatic impairment and overt hepatic encephalopathy. 2013.

Hassanein, Tarek

Page 38

133. A multicenter, randomized, open-label, active-controlled trial to evaluate the safety and efficacy of Rifaximin 550 mg with and without Lactulose in subjects with a history of recurrent overt hepatic encephalopathy. 2013.

134. A randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to

assess the efficacy and safety of Rifaximin soluble solid dispersion (SSD) tablets for the prevention of complications in subjects with early decompensated liver cirrhosis. 2013.

135. A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects. 2013.

136. A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial

Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC). 2013.

137. A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-

450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II) 2013.

138. A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of

the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection () 2013.

139. A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of

Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I). 2013.


Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH). 2013.


Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non- Alcoholic Steatohepatitis (NASH). 2013.

142. A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combination

with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection. 2013.

Hassanein, Tarek

Page 39

143. A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis. 2013.

144. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy East Asian

and Caucasian Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of Single and Multiple Ascending Oral Doses of TG-2349, and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients. 2013.

145. A Phase I Study of LJPC-501 in Patients with Hepatorenal Syndrome (HRS). 2013.

146. An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of

Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead- Sponsored HCV Treatment Study. 2013.

147. A Randomized, Global, Double-blind, Placebo-controlled, Parallelgroup Study to

Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. 2014.

148. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of Single and Multiple Ascending Oral Doses of TG- 2349, and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients. 2014

149. Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy (STOP- HE Study). 2014.

150. A Randomized, Open-label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects with Alcohol Induced Liver Decompensation (AILD). 2014.

151. A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the

Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease. 2014.

152. A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered with Ribavirin (RBV) in Adults with Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis. 2014.

153. An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and

Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection. 2014.

Hassanein, Tarek

Page 40

154. A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection. 2014.

155. Obalon® Balloon System Clinical Investigation Six-Months as Repeated Therapy (SMART) Trial Protocol. March 2015.

156. A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of

the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection. 2015.

157. Phase 4 LIRA-PRIME: Efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting. 2015.

158. A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and

Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD). 2015.

159. Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type

2 diabetes. 2015. 160. A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of

the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC) in Subjects with Chronic HCV GT1 or GT3 Infection who have failed a Direct Acting Antiviral Regimen (MK-3682-021). 2016.

161. 747-303: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled,

Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis. 2016.

162. Obalon The Six-Month Adjunctive Weight Reduction Therapy Continued Access

Research (SMART CAR) Study. 2016. 163. A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and

TD-6450 Alone and in Combination with Other Antivirals for 12 Weeks in Treatment-Naïve Patients Chronically Infected with Genotype 1 Hepatitis C Virus. 2016.

164. A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-

530 in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1). 2016.

165. A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the

Combination Combination Regimen of MK-3682 + MK-8408 in Subjects with Chronic HCV GT1, 2, 3, 4, 5 or 6 Infection. 2016.

Hassanein, Tarek

Page 41

166. An Open-Label, Two-Part, Phase 1, Crossover Study to Determine the Absolute

Bioavailability and Pharmacokinetics of Oral Immediate-Release Doses of OCR-002 in Subjects with Varying Degrees of Cirrhosis. 2016.

167. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety,

Tolerability, and Efficacy of GS-0976 in Subjects with Nonalcoholic Steatohepatitis. 2016.

168. A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of

MGL-3196 in Patients With Non Alcoholic Steatohepatitis. 2016. 169. A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to

Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH). 2016.

170. A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple

Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 weeks in Patients with Primary Sclerosing Cholangitis (PSC). 2016.

171. Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide

once daily versus placebo in subjects with non-alcoholic steatohepatitis. A 72-week randomized, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial. 2016.

172. A randomized, double-blind, placebo controlled, 2-part, adaptive design, multicenter 12-

week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis (NASH). 2016.

173. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety

and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. 2017.

174. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH). 2017.

175. A Randomized, Open-label, Multicenter, Controlled, Pivotal Study to Assess Safety and

Efficacy of ELAD ® in Subjects with Alcoholic-induced Liver Decompensation (AILD). 2017.

176. An Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and

Pharmacokinetics of MN-001 (tipelukast) on HDL (hgh Density Lipoprotein) Function and Serum Triglyceride Levels in Non-Alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects with Hypertriglyceridemia. 2017.

177. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety,

Hassanein, Tarek

Page 42

Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH). 2017.

178. A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and

Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH). 2017.

179. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to

Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis. 2017.

180. An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week

extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA). 2017.

181. A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-dose Study

to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutatneous BFKB8488A in Patinets with Type 2 Diabetes Mellitus. 2017.

182. A randomized, double blind, placebo controlled, multicenter, dose ranging, Phase 2

study, to evaluate the safety and efficacy of EDP-305 in subjects with primary biliary cholangitis (PBC) with or without an inadequate response to ursodeoxycholic acid (UDCA). 2017.

183. A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in

Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma. 2017.

PARTICIPANT: - Nonalcoholic Steatohepatitis Clinical Research Network - Acute Liver Failure Study Group - Latino Study Group - ACHIEVE 1 Study Team - Farglitazar Study Group - PROVE-3 Study Team - Advance Study Team - Liver Cancer Study Group

JOURNAL PUBLICATIONS:

1. Hassanein T. Incidence and etiology of chronic abdominal pain in patients admitted to the Medical Wards of Alexandria University. Master Thesis, Library of Alexandria University, 1987.

2. Rabinovitz M, Zajko AB, Hassanein T, Shetty B, Bron KM, Schade RR, Gavaler JS,

Block G, Van Thiel DH, Dekker A. Diagnostic Value of Brush Cytology in the Diagnosis of Bile Duct Carcinoma: A Study in 65 Patients with Bile Duct Strictures. Hepatology 1990;12:747-752.

Hassanein, Tarek

Page 43

3. Sakr MF, Hassanein TI, Zetti GM, Van Thiel DH. FK 506 Ameliorates the Hepatic Injury Associated with Ischemia. Life Sciences 1990;47:687-691.

4. Hassanein T, Perper JA, Tepperman L, Starzl TE, Van Thiel DH. Liver Failure

Occurring as a Component of Exertional Heatstroke. Gastroenterology 1991;100:1442- 1447.

5. Hassanein TI, Gavaler JS, Fishkin D, Gordon R, Starzl TE, Van Thiel DH. Does the

Presence of a Measurable Blood Alcohol Level in a Potential Organ Donor Affect the Outcome of Liver Transplantation? Alcoholism: Clinical and Experimental Research 1991;15:300-304.

6. Sakr MF, Zetti GM, Hassanein TI, Farghali H, Nalesnik MA, Gavaler JS, Starzl TE, Van

Thiel DH. FK 506 Ameliorates the Hepatic Injury Associated with Ischemia and Reperfusion in Rats. Hepatology 1991;13:947-951.

7. Sakr MF, Zetti GM, Farghali H, Hassanein TH, Gavaler JS, Starzl TE, Van Thiel DH.

Protective Effect of FK 506 against Hepatic Ischemia in Rats. Transplantation Proceedings 1991;23:340-341.

8. Hassanein T, Razack A, Gavaler JS, Van Thiel DH. Heatstroke: Its Clinical and

Pathological Presentation, with Particular Attention to the Liver. The American Journal of Gastroenterology 1992;87:1382-1389.

9. El-Ashmawy L, Hassanein T, Gavaler JS, Van Thiel DH. Prevalence of Hepatitis C

Virus Antibody in a Liver Transplantation Population. Digestive Diseases and Sciences 1992;37:1110-1115.

10. Sakr M, Hassanein T, Gavaler J, Abu-Elmagd K, Fung J, Gordon R, Starzl T, Van Thiel

D. Cytomegalovirus Infection of the Upper Gastrointestinal Tract Following Liver Transplantation-Incidence, Location, and Severity in Cyclosporine- and FK506-Treated Patients. Transplantation 1992;53:786-791.

11. Wright HL, Bou-Abboud CF, Hassanein T,Block GD, Demetris AJ, Starzl TE Van Thiel

DH. Disease Recurrence and Rejection Following Liver Transplantation for Autoimmune Chronic Active Liver Disease. Transplantation 1992;53:136-139.

12. Hassanein T, Schade R. Hemochromatosis. Gastroenterology and Endoscopy News. Oct.

1993;22-28.

13. Hassanein TI, Shetty B, Gavaler JS, Sakr MF, Sheahan DG, Rinaldo C, Van Thiel DH. The timing, location and histologic characterization of upper gastrointestinal cytomegalovirus infection occurring in a liver transplant population. European Journal of Gastroenterology & Hepatology 1993;5:1021-1027.

14. Gurakar A, Fagiuoli S, Hassanein T, Kingery L, Wright HI, Ersoz S, Caraceni P, Gavaler

JS, Van Thiel DH. Prophylactic alpha-interferon therapy following liver transplantation: does it prevent allograft infection? European Journal of Gastroenterology & Hepatology 1994;6:429-432.

15. Gurakar A, Fagiuoli S, Gavaler JS, Hassanein T, Jabbour N, Wright HI, Deal SA, Shah

Hassanein, Tarek

Page 44

A, Brown M, Carr BI Van Thiel DH. The use of granulocyte-macrophage colony stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. Journal of Hepatology 1994;21:582-586.

16. Appasamy R, Bryant J, Hassanein T, Van Thiel DH, Whiteside TL. Effects of Therapy

with Interferon alfa on Peripheral Blood Lymphocyte Subsets and NK Activity in Patients with Chronic Hepatitis C. Clinical Immunology and Immunopathology 1994;73:350-357.

17. Gurakar A, Fagiuoli S, Hassanein T, Wright HI, Balkan M, Frezza E, Todo S, Starzl TE,

Van Thiel DH. Is rejection a diffuse or localized process in small-bowel transplantation? Surgical Endoscopy 1994;8:762-764.

18. Hassanein T, Schade RR, Soldevilla-Pico C, Tabasco-Minguillan J, Abu-Elmagd K,

Furukawa H, Kadry Z, Demetris A, Tzakis A, Todo S. Endoscopy is Essential for Early Detection of Rejection in Small Bowel Transplant Recipients. Transplantation Proceedings 1994;26:1414-1415.

19. Hassanein T, Schade R, Soldevilla-Pico C, Tabasco-Minguillan J, Abu-Elmagd K, Furukawa H, Kadry Z, Demetris A, Tzakis A Todo S. Clinical and Endoscopic Features of Rejection in Small Bowel Transplant Recipients. Transplantation Proceedings 1994;26:1413.

20. Hassanein T, Gurakar A, Wright HI, Van Thiel DH. Major Gastrointestinal Bleeding

Occurring After Liver Transplantation. The Journal of the Oklahoma State Medical Association 1995;88:114-118.

21. Van Thiel DH, Hassanein T,Gurakar A, Caraceni P, Nadir A, Wright HI. The Polka Dot

Liver and Spleen: A Case Report. The Journal of the Oklahoma State Medical Association 1995;88:7-10.

22. Van Thiel DH, Hassanein T. Assessment of Liver Function: The Current Situation. The

Journal of the Oklahoma State Medical Association 1995;88:11-16.

23. Gurakar A, Hassanein T, Van Thiel DH. Right Diaphragmatic Paralysis Following Orthotopic Liver Transplantation. The Journal of the Oklahoma State Medical Association 1995;88:149-153.

24. Van Thiel DH, Nadir A, Hassanein T, Wright HI. Simultaneous Right-sided Volume

Overload and Left-sided Hypovolemia in a Man with Massive Ascites and a Hydrothorax. The American Journal of Gastroenterology 1995;90:478-481.

25. Nadir A, Nadir F, Hassanein T, Gurakar A, Wright HI, Van Thiel DH. Acute Relapsing

Pancreatitis Induced with Ursodeoxycholic Acid Therapy. The Journal of the Oklahoma State Medical Association 1995;88:295-298

26. Van Thiel DH, Caraceni P, DeMaria N, Nadir A, Hassanein T, Nadir F.

Panhypopituitarism in Two Cirrhotics: Clinical Presentation and Liver Disease Associations. The Journal of the Oklahoma State Medical Association 1995;88:299-304.

27. Kowdley KV, Hassanein T, Kaur S, Farrell FJ, Van Thiel DH, Keeffe EB, Sorrell MF,

Hassanein, Tarek

Page 45

Bacon BR, Weber FL, Tavill AS. Primary Liver Cancer and Survival in Patients Undergoing Liver Transplantation for Hemochromatosis. Liver Transplantation and Surgery 1995;1:237-241.

28. Colantoni A, DeMaria N, Hassanein TI,Van Thiel DH. Management of Hepatitis B Pre-

and Post OLTx: a Review and a Look to the Future. Viral Hepatitis 1995;1:157-170.

29. Hassanein T, Van Thiel DH, Guraker A. Gut Permeability. Update in intensive care and emergency medicine. Springer-Verlag (Heidelberg, Germany). 1995;129-144.

30. Hassanein T, Van Thiel DH. Biochemical abnormalities in liver disease. In:

Investigations in Hepatology. Bailliere's Clinical Gastroenterology. Dec 1995;9(4):679- 688.

31. Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson’s disease.

Journal of Hepatology 1995;23:373-391.

32. Van Thiel DH, Caraceni P, Molloy PH, Hassanein T, Kania RJ, Gurakar A Friedlander L. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alfa2b therapy. Journal of Hepatology 1995;23:503-508.

33. Fagiuoli S, Gurakar A, Hassanein T, Wright HI, Van Thiel DH. Liver Resection and

Transplantation. In: Consultations in Gastroenterology. Snape W (ed). W.B. Saunders New York 1996:828-842.

34. Van Thiel DH, Colantoni A, De Maria N, Fagiuoli S, Gasbarrini A, Hassanein T. Liver

transplantation in the United States: Current problems and future goals. Ital J Gastroenterol 1996;28:169-175.

35. Ichida T, Van Thiel DH, Hassanein T. The Medical Management of Hepatocellular

Carcinoma (HCC) in Japan: A Review with Implications for HCC Seen in the West. Hepato-Gastroenterology 1996;43:1575-1583.

36. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Caraceni P, De Maria, N, Nadir A.

Liver Transplantation after an Acute Episode of Spontaneous Bacterial Peritonitis. Hepato-Gastroenterology 1996;43:1584-1588.

37. Hassanein T,Colantoni A, De Maria N, Van Thiel DH. Interferon-alfa 2b improves

short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. Journal of Viral Hepatitis 1996;3:333-340.

38. Friedlander L, Van Thiel DH, Faruki H, Molloy PJ, Kania RJ, Hassanein T. New

Approach to HCV Treatment Recognition of Disease Process as Systemic Viral Infection Rather than as Liver Disease. Digestive Diseases and Sciences 1996;41:1678-1681.

39. Sandford SL, Colantoni A, De Maria N, Hassanein T, Van Thiel D, Tarter RE.

Neuropsychological impairment in a patient with a normal liver and long-standing portacaval anastomosis: studies obtained before and after liver transplantation. European Journal of Gastroenterology & Hepatology 1996;8:919-923.

Hassanein, Tarek

Page 46

40. Hassanein T, Wahlstrom HE. The role of Immune Modulators in the Treatment of Viral Hepatitis. Antiviral Therapy. 1996;1:84-89.

41. Tan HP, Wahlstrom HE, Zamora JU, Hassanein T. Aureobasidium Pneumonia in a Post

Liver Transplant Recipient: A Case Report. Hepato-Gastroenterology 1997;44:1215- 1218.

42. Hassanein TI,Wahlstrom HE, Zamora JU, Van Thiel DH. Conventional Care of

Fulminant Hepatic Failure: Medical and Surgical Aspects. Therapeutic Apheresis 1997;1:33-37.

43. Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van Thiel DH. A Comparison of

the Prevalence of Autoantibodies in Individuals with Chronic Hepatitis C and Those with Autoimmune Hepatitis: The Role of Interferon in the Development of Autoimmune Diseases. Hepato-Gastroenterology 1997;44:417-425.

44. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T,Faruki H. A

preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. Journal of Viral Hepatitis 1997;4:101-106.

45. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T,Wahlstrom HE, Faruki

H. Lamivudine Treatment of Advanced and Decompensated Liver Disease due to Hepatitis B. Hepato-Gastroenterology 1997;44:808-812.

46. Colantoni A, Hassanein T, Idilman R, Van Thiel DH. Liver Transplantation for Chronic

Viral Liver Disease. Hepato-Gastroenterology 1998;45:1357-1369.

47. Buck M, Kim DJ, Houglum K, Hassanein T, Chojkier M. c-Myb modulates transcription of the ∝-smooth muscle acting gene in activated hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2000;278:G321-G328.

48. Lonergan JT, Behling C, Pfander H, Hassanein T, Mathews WC. Hyperlactatemia and

Hepatic Abnormalities in 10 Human Immunodeficiency Virus Infected Patients Receiving Nucleoside Analogue Combination Regimens. Clinical Infectious Diseases 2000;31:162-6.

49. Rose S, Pretorius D, Nelson T, Kinney T, Huynh T, Roberts A, Valji K, D’Agostino H,

Oglevie S, James G, Hassanein T, Hart M, Orloff M. Adjunctive 3D US for Achieving Portal Vein Access During Transjugular Intrahepatic Portosystemic Shunt Procedures. JVIR 2000.

50. Rose, SC, Hassanein TI, Easter DW, Gamagami RA, Bouvet M, Pretorius DH, Nelson

TR, Kinney TB, James GM. Value of three dimensional US for optimizing guidance for ablating focal liver tumors. Journal of Vascular and Interventional Radiology 2001;12:507-15.

51. Allen JW, Hassanein T, Bhatia SN. Advances in Bioartificial Liver Devices. Hepatology

2001 (3);34:447-455.

52. Rose SC, Andre MP, Roberts AC, Kinney TB, Valji K, Ronaghi AH, Hassanein TI, Lavine JE, Hart ME, Khanna A. Integral role of interventional radiology in the

Hassanein, Tarek

Page 47

development of a pediatric liver transplantation program. Pediatric Transplantation 2001;5:331-338.

53. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum

Aminotransferase Levels and Platelet Counts as Predictors of Degree of Fibrosis in Chronic Hepatitis C Virus Infection. Amer Jour of Gastro 2002;96:3142-3146.

54. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological Impairment In patients with

Chronic Hepatitis C. Hepatology 2002:440-446.

55. Stange J, Hassanein T, Mehta R, Mitzner S, Bartlett. The Molecular Adsorbents Recycling System as a Liver Support System Based on Albumin Dialysis: A Summary of Preclinical Investigations, Prospective, Randomized, Controlled Clinical Trail, and Clinical Experience from 19 Centers. Artificial Organs: 2002;26(2):103-110.

56. Rose S, Behling C, Roberts A, Pretorius D, Nelson T, Kinney T, Masliah E, Hassanein T.

Main Portal Vein Access in Transjugular Intrahepatic Portosystemic Shunt Procedures: Use of the Three-dimensional Ultrasound to Ensure Safety. J Vasc Interv Radiol 2002: 267-273.

57. Rose SC, Hassanein TI, Bouvet M, Hart ME, Khanna A, Saville MW. Delivery of

radiofrequency ablation probes to the targeted liver malignancy; using all the players on the field. J Vase Interv Radiol. 2002 Oct:13(10):1060-1

58. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents

recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002 Feb 26(1):103-110

59. Dieterich D, Wasserman R, Brau N, Hassanein T, Bini, E, Bowers, P, Sulkowski M.

Once-weekly Epoetin Alfa Improves Anemia and Facilitates Maintenance of Ribavirin Dosing in Hepatitis C Virus-Infected Patients Receiving Ribavirin Plus Interferon Alfa. Am J Gastroenterol 2003;98:2491-2499.

60. Diago M, Hassanein T, Rodés J, Ackrill AM, Sedarati F. (Letter) Optimized Virologic

Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and Ribavirin. Ann Intern Med 2004;140:72-73.

61. Zeh N, Rossi SS, Hofmann AF, Steinbach JH, Hagey LR, Oliver D, Stange J, Hassanein

T. The effect of extracorporeal albumin dialysis on plasma phospholipid fatty acids in patients with end-stage liver disease. Liver Int. 2003;23 Suppl 3:34-8.

62. Hassanein T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with

superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs. Liver Int. 2003;23 Suppl 3:61-5.

63. DiBisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain

KB, Gish R, VanThiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS, Liver Cancer Network. Hepatitis C-related Hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, 2003 Sep;98(9);2060-3.

Hassanein, Tarek

Page 48

64. Hilsabeck RC, Hassanein T, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003 Sep;9(6):847-54.

65. Hilsabeck RC, Hassanein TI. Hepatitis C & Cognitive Impairment. The HCV Advocate Medical Writers’Circle. August 2003

66. Kinney TB, Ferrara SL, Miller FJ, Roberts AC, Hassanein T. Transjugular intrahepatic

portosystemic shunt creation as treatment for refractory chylous ascites and chylothorax in a patient with cirrhosis. J Vasc Interv Radiol. 2004 Jan;15(1 Pt 1):85-9.

67. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G,

Treho-Estrada R, Horta E, Vale A, Wintfeld N, Green J. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol, 2004 Apr;40(4):675-81.

68. Radhakrishna Pillai G, Srivastava AS, Hassanein T, Chauhan DP, Carrier E. Induction of

apoptosis in human lung cancer cells by curcumin. Cancer Letters 2004 May 28;208(2):163-70.

69. Sullivan SD, Jensen DM, Bernstein DE, Hassanein T, Foster GR, Lee SS, Cheinquer H,

Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J. Cost-Effectiveness of Combination Peginterferonalpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C. Am J Gastroenterol. 2004 Aug:99(8):1490-6

70. Hassanein T, Frederick T. Mitochondrial dysfunction in liver disease and organ

transplantation. Mitochondrion. 2004 Sep;4(5-6):609-20. Erratum in: Mitochondrion. 2006;6(2):104.

71. Hilsback RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of Interferon-

alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2005 Jan;11(1):16-22.

72. Fredrick RT, Hassanein TI. Role of growth factors in the treatment of patients with

HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. J Clin Gastroenterol. 2005 Jan;39 (I Suppl);S14-22. Review.

73. Waris G, Turkson J, Hassanein T, Siddiqui A. Hepatitis C Virus (HCV) Constitutively

Activates STAT-3 via Oxidative Stress: Role of STAT-3 in HCV Replication. J Virol 2005 Feb:1659-1580

74. Puckett, JL., Liu J, Bhalla V, Kravetz D, Krinsky ML, Hassanein T, Mittal RK.

Ultrasound system to measure esophageal varix pressure: an in vitro validation study. AJP Physiol Gastrointest Liver Physiol . 2005 May;288:G914-9.

75. Hilsabeck, R.C., Hassanein, T.I.,Perry, W. (2005). Biopsychosocial predictors of fatigue

in chronic hepatitis C. Journal of Psychosomatic Research, 58, 173-178.

76. Chen J, Lin RK, Hassanein T. Use of Orlistat (Xenical) to Treat Chylous Ascites. J Clin Gastroenterol 2005 Oct: 39(9); 831-833.

Hassanein, Tarek

Page 49

77. Perry W, Carlson MD, Barakat F, Hilsabeck RC, Schiehser DM, Mathews C, Hassanein TI. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS. 2005 Oct;19 Supple 3:S79-84

78. Swaminath A, Oliver D, McNeil AC, Hassanein TI.The Influcence of HIV Coinfection

on the Natural History of HCV Infection. Current Hepatitis Reports. 2005 Nov: 4(4)

79. Khanna A, Hart M, Nyhan WL, Hassanein T, Panyard-Davis J, Barshop BA. Domino liver transplantation in maple syrup urine disease. Liver Transplantation. 2006 May; 12(5): 876-882

80. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive

diagnosis with double contrast material-enhanced MR imaging. Radiology. 2006 May;239(2):425-37.

81. Rutherford A, Daverne T, Hay JE, Murray NG, Hassanein T, Lee WM, Chung RT. Acute

Liver Failure Study Group. Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1544-9. Epub 2006 Sep 25.

82. Kono Y, Lucidarme O, Choi SH, Rose SC, Hassanein TI, Alpert E, Mattrey RF.

Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiology. 2007 Jan;18(1 Pt 1):57-65.

83. Møller HJ, Gronbaek H, Schiodt FV, Holland-Fischer P, Schilsky M, Munoz S,

Hassanein T, Lee WM; US Acute Liver Failure Study Group. Soluble CD163 from activated machrophages predicts mortality in acute liver failure. J Hepatol. 2007;47(5):671-6. Epub 2007 Jun 21.

84. Hassanein T, Shiffman ML, Zein NN. The practical management of treatment failure in

chronic hepatitis C: a summary of current research and management options for refractory patients. Gastroenterol Hepatol (N Y). 2007 Jun;3(6 Suppl 20):4-32.

85. Perry W, Hilsabeck RC, Hassanein TI.Cognitive dysfunction in chronic hepatitis C: a

review. Dig Dis Sci. 2008. Feb;53(2):307-21. Epub 2007 Aug 17. Review.

86. Hassanein TI,Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci. 2008 Feb;53(2):529-38. Epub 2007 Aug 21.

87. Hughes-Cassidy F, Chavez AD, Schlang A, Hassanein T, Gamst A, Wolfson T, Sirlin C.

Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis. J Magn Reson Imaging. 2007 Sep;26(3):728-37.

Hassanein, Tarek

Page 50

88. Hassanein TI,Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS,

Gornbein J, Stange J, Blei AT. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007 Dec;46(6):1853-62.

89. Hanna RF, Kased N, Kwan SW, Gamst AC, Santosa AC, Hassanein T,Sirlin CB.

Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol. 2008 Jan;190(1):47-57.

90. Vigil O, Posada C, Woods SP, Atkinson JH, Heatoln RK, Perry W, Hassanein TI, Grant

I, Letendre SL, Group TH. Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. J Clin Exp Neuropsychol. 2008 Mar 4:1-11.

91. Fish EN, Harrison SA, Hassanein T. The role of consensus interferon in the current

treatment of chronic hepatitis C viral infection. Gastroenterol Hepatol (N Y). 2008 Sep;4(9 18):1-12.

92. Bacon BR, Shiffman ML, Mendes F, Ghalib R, Hassanein T, Morelli G, Joshi S,

Rothstein K, Kwo P, Gitlin N. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Feb 2.

93. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, Hassanein T,

Patton HM, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic Fatty Liver Disease: Diagnostic and Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled- Echo MR Imaging at 1.5 T. Radiology. 2009 Feb 12.

94. Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T,

Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol. 2009 Apr;7(4):397-414.

95. Hassanein T, Blei AT, Perry W, Hilsabeck R, Stange J, Larsen FS, Brown RS, Caldwell

C, McGuire B, Nevens F, Fontana R. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol 2009 May;104-:1392-1400.

96. Brixner DI, Ye X, Chu T, Blumentals WA, Hassanein T. Treatment persistence in and

cost of therapy for patient with chronic hepatitis C: Peginterferon alfa-2a plus ribavrin versus peginterfeorn alfa-2b plus ribavirin. Am J Health-Syst Pharm 2009 Dec;66.

97. Posada C, Moore DJ, Woods SP, Vigil O, Ake C, Perry W, Hassanein TI, Letendre SL,

Grant I, HNRC Group. Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living. J Clin and Experimental Neuropsychology 2010, 32(6), 637-644.

98. Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman

D, Chun E, Hammond J. Virological response rates of weight-based taribavirin versus ribavirin in treatment-naïve patients with genotype 1 chronic Hepatitis C. Hepatology 2010 Oct;52;(4).

Hassanein, Tarek

Page 51

99. Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, DiBisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon afla-2a/ribavirin in chronic Hepatitis C. Hepatology. 2010 Dec;52(6).

100. Farag NH, Hebat-Allah R, Hasssan M, Darweesh A, Shehata Mo, Hassanein T, Mills PJ.

Hepatitis C Infection, Cognition, and Inflammation in an Egyptian Sample. J Med Virol. 2011 83:261-266.

101. Talal AH, Liu RC, Zermeski M, Dimova R, Dove L, Pearce D, Hasssanein T, Doonquah

L, Aboulafa D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson MI. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/HCV patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Synd. 2011 Aug 25.

102. Low RN, Hassanein T. Non-invasive evaluation of liver disease using MR elastrography.

SignaPulse 2011.

103. Hassanein T, Schade RR, Hepburn IS. Acute-on-chronic liver failure: extracorporeal liver assist devices. Curr Opin Crit Care 2011;17;195-203.

104. Xiao XQ, Hassanein T, Li QF, Liu W, Zheng YH, Chen J. YKL-40 expression in human

hepatocellular carcinoma: a potential biomarker? Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):605-10.

105. Sakamoto M, Perry W, Hilsabeck RC, Barakat F, Hassanein T. Assessment and

usefulness of clinical scales for semiquantification of overt hepatic encephalopathy. Clin Liver Dis. 2012 Feb;16(1):27-42.

106. Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serrão R,

Sola R, Bertasso A, Passe And S, Stancic S. Peginterferon alfa-2a plus ribavirin for HIV- HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 2012 May-Jun;13(3):142-52.

107. Bahl G, Cruite I, Wolfson T, Gamst AC, Collins JM, Chavez AD, Barakat F, Hassanein

T, Sirlin CB. Noninvasive classification of hepatic fibrosis based on texture parameters from double contrast-enhanced magnetic resonance images. J Magn Reson Imaging. 2012 Nov;36(5):1154-61.

108. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH,

Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013 May;13(5):401-8.

Hassanein, Tarek

Page 52

109. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15;381(9883):2100-7.

110. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz

M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16;368(20):1878-87.

111. Syed GH, Tang H, Khan M, Hassanein T, Liu J, Siddiqui A. Hepatitis C Virus stimulates

Low-Density Lipoprotein Receptor (LDLR) expression to facilitate viral propagation. J Virol. 2014 Mar; 88(5): 2519-29.

112. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I,

Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM; AI444040 Study. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21

113. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski

MS, Wedermeyer H, Tam E, Desmond P, Jensen DM, DiBisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-Ombitasivr and Dasabuvir with Ribavirin. N Engl J Med. 2014 Apr 24;370(17): 1604-14.

114. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai

N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med. 2014 May 4.

115. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi

Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. A Randomized Trial of Daclatasvir in Combination with Asunaprevir and Beclabuvir in Patients with Chronic Hepatitis C Virus Genotype 4 Infection. J Hepatol. 2014 Dec 25.

116. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T,

Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec 6.

Hassanein, Tarek

Page 53

117. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K,

Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. Obmitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomized open-label trial. Lancet. 2015 Jun20;385(9986):2502-9.

118. Pol S, Sulkowski MS, Hassanein T, Gane EJ, Liu L, Mo H, Doehle B, Kanwar B,

Brainard D, Subramanian GM, Symonds WT, McHutchison JG, Nahass RG, Bennett M, Jacobson IM. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology. 2015 Jul;62(1):129-34.

119. Halldorson J, Kazi Z, Mekeel K, Kuo A, Hassanein T, Loomba R, Austin S, Valasek

MA, Kishnani P, Hemming AW. Successful combined liver/kidney transplantation from a donor with Pompe disease. Mol Genet Metab. 2015 Aug;115(4):141-4.

120. Hezode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M; COMMAND-4 study team. Antivir Ther. 2015 Aug 27;21(3):195-205.

121. Morgan TR, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu KQ, Hassanein T, Boyer

TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL. A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prev Res (Phila). 2015 Sep;8(9):864-72.

122. Venditti I, Hassanein TF, Fratoddi I, Fontana L, Battocchio C, Rinaldi F, Carafa M, Marianecci C, Diociaiuti M, Agostinelli E, Cametti C, Russo MV. Bioconjugation of gold-polymer core-shell nanoparticles with bovine serum oxidase for biomedical applications. Colloids Surf B Biointerfaces. 2015 Oct 1;134:314-21.

123. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S,

Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W. Grazoprevir plus elbasivir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015 Oct 17;386(10003): 1537-45.

124. Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naïve patients. Liver Int. 2016 Feb;36(2):189-97.

Hassanein, Tarek

Page 54

125. Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S, Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J. Ritonavir-boosted danoprevir-based regimens in treatment-naïve and prior null-responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatol Int. 2016 May; 10(3):478-87.

126. Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic resonance elastrography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016 May;26(5):1431-40.

127. Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS One. 2016 Mar 28;11(3).

128. Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, Durkalski V,

Larson AM, Liou I, Fix O, Schilsky M, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Smith A, Brown R, Crippin J, Harrison ME, Koch D, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hassanein T, Hanje AJ, Olson J, Subramanian R, Karvellas C, Hameed B, Sherker AH, Robuck P, Lee WM. Outcomes in Adults with Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. Ann Intern Med. 2016 Jun 7;164(11):724-32.

129. Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld

JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):25-35. doi: 10.1016/S2468-1253(16)30001-2. Epub 2016 Jun 16.

130. Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P,

Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype01: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun;15(3):333-49.

131. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T,

Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016 Oct;151(4):651-659.

132. Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, Chalasani NP,

Lim JK, Reuben A, Vargas HE, Abrams G, Lewis MD, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND, Groszmann RJ; Vapreotide Study Group. Child-Turcotte-Pugh is best at stratifying risk in variceal hemorrhage: Analysis

http://www.ncbi.nlm.nih.gov/pubmed/28404108



Hassanein, Tarek

Page 55

of a US Multicenter Prospective Study. J Clin Gastroenterol. 2016 Oct 24. 133. Terrault NA, Hassanein TI. Management of the patient with SVR. J Hepatol. 2016

Oct;65(1 Suppl):S120—S129. 134. Hassanein T. Hepatitis B Virus: The Past, The Present, and The Future. Clin Liver Dis.

2016 Nov;20(4):ix-x. 135. Luvisa BK, Hassanein T. Hepatitis B Virus Infection and Liver Decompensation. Clin

Liver Dis. 2016 Nov;20(4):681-692. 136. Hassanein T. Current state of knowledge of hepatic encephalopathy (part IV):

Management of Hepatic Encephalopathy by liver support systems. Metab Brain Dis. 2017 Apr;32(2):303-306.

137. Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, Bernstien D, Maruyama

H, Saraswat V, Chawla Y, Hamid S, Abbas Z, Bedossa P, Sakhuja P, Elmahatab M, Lim SG, Lesmana L, Sollano J, Jia JD, Abbas B, Omar A, Sharma B, Payawal D, Abdallah A, Serwah A, Hamed A, Elsayed A, AbdelMaqsod A, Hassanein T, Ihab A, GHaziuan H, Zein N, Kumar M. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017 Jan;11(1):1-30.

138. Pozza R, Hill C, Hefner AM, Vawter B, Hassanein T. Hepatitis C infection: Updates on treatment guidelines. Nurse Pract. 2017 May 12;42(5):14-23.

139. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F,

Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Aug;67(2):263-271.

140. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T,

Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017 Oct;17(10):1062-1068.

141. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K,

Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2017 Sep 19.

142. Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI,

Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM.












Hassanein, Tarek

Page 56

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823.

143. Thompson J, Jones N, Al-Khafaji A, Malik S, Reich D, Munoz S, MacNicholas R, Hassanein T, Teperman L, Stein L, Duarte-Rojo A, Malik R, Adhami T, Asrani S, Shah N, Gaglio P, Duddempudi A, Borg B, Jalan R, Brown R, Patton H, Satoskar R, Rossi S, Parikh A, ElSharkawy A, Mantry P, Sher L, Wolf D, Hart M, Landis C, Wigg A, Habib S, McCaughan G, Colquhoun S, Henry A, Bedard P, Landeen L, Millis M, Ashley R, Frank W, Henry A, Stange J, Subramanian R; VTI-208 Study Group. Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis - A Multinational, Prospective, Controlled, Randomized Trial. Liver Transpl. 2017 Nov 24.

144. Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating

hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. J Hepatol. 2017 Dec 8.

145. Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M,

Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426.

SELECTED ABSTRACTS:

1. Hassanein TI, Sakr M, Shetty B, Maxxaferro V, Gavaler JS, Van Thiel DH. Hemosiderosis: its impact on subsequent OLTx. American Gastroenterological Association. Gastroenterology 1990;98:A592.

2. Hassanein T, Fishikin D, Gavaler JS, Van Thiel DH. Effect of donor blood alcohol level

on transplant outcome. Gastroenterology 1990;98:A592.

3. Hassanein T, Shetty B, Sheahan DG, Rabinovitz M, Reddy S, Schade RR, Gavaler J, Van Thiel DH. The prevalence of helicobacter pylori (Hp) infection is reduced post-OLTx despite the presence of chronic active gastritis. Gastroenterology 1990;98:A56.

4. Shetty B, Hassanein T, Gavaler JS, Van Thiel DH, Rinaldo C, Sheahan D. CMV

infection following OLTx. Gastroenterology 1990;98:A123.

5. E, MurrayRabinovitz M, Shetty B, Hassanein T, Schade RR, Gavaler JS, Van Thiel DH, Iwatsuki S, Dekker A. Usefulness of brush cytology in the diagnosis of bile duct carcinoma (BDC) Gastroenterology 1990;98:A305.

6. Sheahan DG, Shetty B, Hassanein T, Iwaki Y, Gavaler JS, Van Thiel DH. Duodenal

atrophy in patients with cirrhosis of the liver. Gastroenterology 1990;98:A474.

7. Sakr M, Hassanein T, Zetti G, Van Thiel DH. FK506 Ameliorates the hepatic injury associated with ischemia. Gastroenterology 1990;98:A627.








Hassanein, Tarek

Page 57

8. Bou-Abboud CF, Block GD, Hassanein T, Demetrius AJ, Starzl TE, Van Thiel DH.

Association of HLA-DR3 with recurrence and rejection after liver transplantation (OLTx) for autoimmune liver disease. Gastroenterology 1990;98:A571.

9. Hassanein T, Gabbour N, Soldevila-Pico C, Nour B, Doddson F, Orons P, Martin M,

Zajko A, Schade R, Fung J. The impact of Tips procedure on liver transplantation. Hepatology 1993;18:A333.

10. Yossef SM, Hassanein T, El-Ashmawy, L, Melhem M, Ghaffar YA, Kania R, Van Thiel

DH, Whiteside, T. Expression of cytokines mRNA in liver biopsies of patients with chronic hepatitis B infection and patients with schistosomiasis mansoni using in-situ hybridization. Hepatology 1993;18:A263.

11. Kowdley KV, Kaur S, Hassanein T, Farrell FJ, Sorrell MF, Van Thiel DH, Keeffe EB,

Bacan BR, Weber FL, Tavill AS. Prevalence of primary liver cancer (PLC) and survival in hereditary hemochromatosis (HHC) patients undergoing orthotopic liver transplantation (OLT). Hepatology 1993;18:A57.

12. Yossef SM, Ghaffar YA, Hassanein T, Salah SA, Molloy PJ, Diamond H, Friedlander L,

Whiteside T, Kania R, Van Thiel DH. Serum cytokine levels in Egyptians with schistosomiasis with and without chronic hepatitis B. Hepatology 1993;18:A218.

13. Guraker A, Fagiuoli, Faruki H, Wright H, Hassanein T, Gavaler JS, Van Thiel DH. Failure of prophylactic alpha interferon (IFN) to inhibit HCV replication and disease recurrence following liver transplantation of patients with HCV-Ab positive liver disease. Hepatology 1993;18:A332.

14. Hassanein T, Fagiuoli S, Gurakar , Wright HI, Van Thiel DH. Interferon treatment of

anti HCV positive individuals who also have markers of autoimmune liver disease. Gastroenterology 1993;104:A913.

15. Fagiuoli S, Hassanein T, Gurakar A, Cararcini P, Wright HI, Tabasco-Miguillan J,

Gavaler JS, Deal S. Liver transplantation for hereditary hemochromatosis (HHC). Gastroenterology 1993;104:A898.

16. Gurakar A, Fagiuoli S, Hassanein T, Ersoz S, Wright HI, Kingery L, Gavaler JS, Van

Thiel DH. The role of early initiation of alpha-interferon (IFN) in the prevention of liver allograft reinfection with either HBV or HCV hepatitis. Gastroenterology 1993;104:A711. (Poster)

17. Tabasco-Minguillan J, Mazariegos G, Hassanein T, Gayowski T, Mieles L, Gavaler J,

Van Thiel DH, Starzl TE. Results of liver transplantation in American veterans with alcoholic cirrhosis. Gastroenterology 1993;106:A1003.

18. Gurakar A, Balkan M, Fagiuoli S, Hassanein T, Gavaler JS, Wright HI, Van Thiel DH.

Anxiety and pain following percutaneous liver biopsy: a comparison of two different needles. Gastroenterology 1993;104A10.

Hassanein, Tarek

Page 58

19. Hassanein T, Schade R, Tabasco-Minguilan, Soldevila-Pico C, Abu-Elmagd K, Furukawa H, Kadry Z, Demetris A, Takis A, Todo S. Endoscopy is essential for early detection of rejection in small bowel transplant recipients. The Third International Symposium on Small Bowel Transplantation. November 1993, Paris, France. Transplantation Proceeding 1994;26:1414-1415. (Oral)

20. Hassanein T,Schade R, Soldevila-Pico C, Tabasco-Minguilan J, Abu-Elmagd K,

Furukawa K, Kadry Z. Clinical and endoscopic features of rejection in small bowel transplant recipients. The Third International Symposium on Small Bowel transplantation. November, 1993, Paris, France. (Poster) World Congresses of Gastroenterology Transplantation Proceedings 1994;26:1413 (Oral).

21. Hassanein T, Schade R, Baikovitz H, Tabasco-Minguilan J, Furukawa H, Abu-Elmagad

K, Todo S. Magnifying endoscopy in small bowel transplant patients. Gastrointestinal Endoscopy 1994;40:P22. (Poster)

22. Hassanein T, Schade R, Belle S, Soldevilla-Pico C, Furukawa H, Abu-Elmagd K,

Demetris J, Todo S. Clinical endoscopic features of rejection in small bowel transplant recipients. Gastrointestinal Endoscopy 1994;40:P22. (Poster)

23. Hassanein T, Cicalese L, El-Ashmawy L, Schade R, Whiteside T, Furukawa H, Abu-

Elmagd K, Todo S. Decreased IGA levels in the ileal mucosa of small bowel transplant (SBT) grafts. Gastroenterology 1994;106:A697. World Congresses of Gastroenterology.

24. Hassanein T, Schade R, Lasky S, Van Thiel DH. Is interferon an immunosuppressant?

Gastroenterology 1004;106:A905.

25. Van Thiel DH, Fagiuoli S, Caraceni P, Wright HI, Gurakar A, Hassanein T. Cryoglobulinemia: A cause for false negative PCR tests in patients with HCV chronic liver disease. Gastroenterology 1994;106:A1002. (Poster)

26. Baddour H, Baker J, Harlan J, Gurakar A, Hassanein T, Fagiuoli S, Caraceni P, Wright

HI, Van Thiel DH. High prevalence and intensity of dental disease in patients referred to a liver transplant center. Gastroenterology 1994;106:A862. (Poster)

27. Baddour H, Gurakar A, Hassanein T, Fagiuoli S, Caraceni P, Wright HI, Van Thiel DH.

Sinus disease: A source of unsuspected pathology in patients with end stage liver disease. Gastroenterology 1994;106:A862. (Poster)

28. Hassanein T, El-Ashmawy L, Melhem M, Schade RR, Whiteside T. Expression of

interferon alpha and gamma genes in liver tissue of patients with chronic hepatitis C infection. Hepatology 1994;20:A621. (Poster)

29. Hassanein T, Finkelstein SD, El-Ashmawy L, Faruki H, Bakkar A, Swalski PA,

Whiteside T, Van Thiel D, Schade RR. Effect of immunotherapy on HCV genotype. Hepatology 1994;20:A258. (Poster)

30. Hassanein T, Bronsther O, Tabasco-Minguillan J, Fung J, Schade RR. Thymosin alpha-1

treatment before liver transplantation in a patient with chronic HBV. Hepatology 1994;20:A161. (Poster)

Hassanein, Tarek

Page 59

31. Hassanein T, Nussler A, Friedlander L, Van Thiel DH. Responses to interferon therapy in chronic hepatitis C are associated with an increase in plasma no. Hepatology 1994;20:A257. (Poster)

32. Faruki H, Hassanein T, Ndimbie OK, Schade R. Comparison of HBV DNA quantities by

two different assays: clinical implications. Hepatology 1994;20:A298. (Poster)

33. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Caraceni P, DeMaria N, Hassanein T, Nadir A. Treatment of HCV-RNA positive individuals with normal or near normal ALT levels. Hepatology 1994;20:A260.

34. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Caraceni P, DeMaria N, Nadir A.

How soon after the initiation of treatment of an episode of spontaneous bacterial peritonitis can an individual safely receive a liver transplant? Hepatology 1994;20:A1255.

35. Hassanein T, El-Ashmawy L, Stanson J, Schade R, Van Thiel DH, Todo S, Abu-El-

Maged K, Whiteside T. Expression of IL-2, IL-IB and TNF alpha genes in the mucosa of intestinal allografts: The role of allograft rejection and CMV infection. Gastroenterology 1995;108:A1081.

36. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Kania R, Molloy P, Friedlander L,

Van Hooser V, Jones S. New autoimmune disease onset under interferon alpha therapy of chronic hepatitis C. Gastroenterology 1995;108:A934. (Poster)

37. Fagiuoli S, Jazzar A, DeMaria N, Faruki H, Deal S, Hassanein T, Colantoni A, Sisson S,

Tripp J, Gavlaer JS, Van Thiel DH, Cooper D, Zuhdi N. Prevalence of HCV infection after heart transplantation. Gastroenterology 1995;108:A1063. (Poster)

38. Gurakar A, Harnish MJ, Hassanein T, Van Thiel DH, Orr WC. Sleep pattern occurring in

individuals with hepatitis C. Gastroenterology 1995;108:A1077. (Poster)

39. Van Thiel DH, Friedlander L, Hassanein T, Gurakar A, Wright H, Molloy PH, Kania RJ, Faruki H. Evidence that the duration of IFN Therapy should be tailored to the virologic response to treatment using more than one in vivo reservoir of infection. Gastroenterology 1995;108:A1192. (Poster)

40. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Nour B, Katz E. Liver

transplantation for isolated primary biliary cirrhosis with associated autoimmune disease (the PBC-overlap syndrome): Is there a difference in prognosis? Gastroenterology 1995;108:A1192.

41. Van Thiel DH, Hassanein T, Nelson D, Cooper D, Samara S, Zuhdi N. Solid organ

transplantation of HTLV-I/II seropositive individuals. Gastroenterology 1995;108:A1193.

42. Van Thiel DH, Rossaro L, Hassanein T, Van Hooser V, Gurakar . The use of ganciclovir

plus GM-CSF to clear HVB-DNA prior to liver transplantation. Gastroenterology 1995;108:A1193.

Hassanein, Tarek

Page 60

43. Van Thiel DH, Molloy PJ, Kania RJ, Hassanein T, Faruki H, Friedlander L. The use of GM-CSF plus IFN to achieve biochemical and virologic resolution of chronic hepatitis C in prior IFN non-responders. Gastroenterology 1995;108:A1103.

44. Gaweco A, Van Thiel DH, Rustgi V, Hassanein T, El-Ashmawy L, Whiteside T,

Hofmann WJ, Otto HF. Th1 cytokine pattern and defective IL-10 in chronic hepatitis C virus-infected livers. American Association for the Study of Liver Diseases. Hepatology 1995;22:915. (Poster)

45. Gaweco A, Rustgi V, Hassanein T, El-Ashmawy L, Whiteside T, Hofmann WJ, Van

Thiel DH, Otto HF. Defective antiviral cytokines in chronic hepatitis C virus-infected livers. American Association of the Study of Liver Diseases Hepatology 1995;22:917. (Poster)

46. Bayraktar M, Bayrakatar A, Gurakar A, Hassanein T, Van Thiel DH. Comparison of the

prevalence of auto-antibodies in chronic hepatitis C patients with those of auto-antibodies in autoimmune hepatitis patients. Hepatology 1995;22:1146.

47. Hassanein T, Van Thiel DH, Frank H, Gurakar A, Van Hooser V. The prevalence of

chronic hepatitis at a methadone clinic. Hepatology 1995;22:A426.

48. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Faruki H, Nour B, Katz E, van Hooser V, Jones S, Kraft P, Reynolds P, Cralson J, Mason K. The use of IFN-Alpha in Liver Transplant Recipients with HCV-RNA Positivity. Gastroenterology 1995;108:A1193.

49. Hassanein T, Freeman J, Oculam CA, Albanese L, Zamora JU, Wahlstrom HE.

Successful early steroid withdrawal using a tacrolimus and mycophenolate protocol for liver transplantation. American Association of the Study of Liver Diseases. Hepatology 1996;24:1579.

50. Zamora JU, Hassanein T, Oculam CA, Albanese L, Wahlstrom HE. HCV seropositivity

is associated with decreased rejections and increased infections after kidney and pancreas transplantation. American Association of the Study of Liver Diseases. Hepatology 1996;24:1898.

51. Wahlstrom HE, Zamora JU, Hassanein T, Issacs B, Kirsch W. Successful use of vascular

clips in liver transplantation. American Association of the Study of Liver Diseases. Hepatology 1996;24;1876.

52. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, Faruki

H. Lamivudine treatment of advanced decompensated liver disease due to hepatitis B. Gastroenterology 1997;112:A1407.

53. Mutchnick M, Tamburro C, Hassanein T, Tong M, Herrera J, Conrad A, Russell J, Blatt

L. Assessment of HCV RNA and HCV Genotype from 1510 Chronic HCV Patients Treated in Community Clinical Practice in the United States Gastroenterology 1997;112:A1279.

Hassanein, Tarek

Page 61

54. Hassanein T, DeGuzman l, Bell L. High dose interferon alfa-2b is more effective in achieving viral negativity in both naïve patients and in previous non-responders with chronic hepatitis C infection. Gastroenterology 1997;112:A1254.

55. DeGuzman L, Bell L, Hassanein T. Tolerance and complications of daily high dose

interferon alpha-2b. Gastroenterology 1997;112:A1254.

56. Hassanein T, DeGuzman LJ. Induction therapy with interferon alpha-2b induces rapid clearance of hepatitis C viremia in naïve patients. Hepatology 1997;26:1572.

57. De Guzman LJ, El-Mola T, Hassanein T. Induction therapy with interferon alpha- 2b

induces rapid clearance of hepatitis C viremia in relapsers. Hepatology 1997;26:1473.

58. Mutchnick M, Tamburro C, Hassanein T, Tong M, Herrera J, Conrad A, Russel J, Blatt L. Analysis of HCV-RNA concentrations by a multi-cycle RT-PCR assay in 3538 untreated chronic HCV patients: Assessment of RNA titer by HCV genotype. Hepatology 1997;26:231.

59. Hassanein T, Behling C, Chatfield E, Monson P, Nguyen T. Maintenance of Interferon

Therapy Inhibits Progression of Cirrhosis in Chronic Hepatitis C Infection. AJG 1998;93:A447.

60. Hassanein T, Monson P, Chatfield E, DeGuzman L, El-Mola T. High ANA Levels Do

Not Preclude Interferon Therapy in Patients with Chronic Hepatitis C Infection. AJG 1998;93:A269.

61. Hassanein T, Monson P, DeGuzman LJ, Nguyen TY, Lyche KD, Chatfield ER, Hanson

K, Rond RL, El-Mola TM, Hardison WG. In HCV Relapsers: Induction Course of Interferon Alfa 2B Improved the Response to Combination Therapy. Hepatology 1998;28:578A.

62. Hassanein T, Monson P, Nguyen TY, DeGuzman LJ, Lyche KD, Chatfield ER, Hanson K, Rond RL, El-Mola TM, Hardison WG. In HCV Non-Responders: Combination Therapy is More Effective Than Induction Therapy in Achieving Viral Clearance. Hepatology 1998;28:571A.

63. Hassanein T, DeGuzman, LJ, Monson P, El-Mola TM, Hanson K, Chatfield ER, Hart

ME. Prolonged HCV-Suppression Using Daily Interferon Alfa Increases the Sustained Response in Naïve Patients. Hepatology 1998;28:713A.

64. Hassanein T, Martin R, Mehta R, Ward D, Hart M. Neurologic Improvement in Deeply

Comatose patients in Acute On Chronic Liver Failure Treated with Extracorporeal Blood Detoxification. Hepatology 1998;28:750A.

65. Hassanein T, Hart ME, Monson P, Chatfield ER, Hwang S. Lamivudine Improves the

Cholestatic Phase of Acute Hepatitis B Infection. Hepatology 1998;28:727A.

66. Huang SM, DeGuzman LJ, Chan DC, Hassanein TI, Lawson T. Iron Saturation Levels May Predict Response to Induction Dose Interferon Therapy in Patients with Chronic Hepatitis C Infection. Hepatology 1998;28:A1660.

Hassanein, Tarek

Page 62

67. DeGuzman LJ, Chan DC, Huang SM, Hassanein TI, Hanson K, Leckernby DL. Induction

Therapy with Interferon Alpha-2B Increases Clearance of Hepatitis C Viremia in Naïve Patients. Hepatology 1998;28:A2440.

68. Hassanein T, Monson P, Behling C, Chatfield E, Taha H, Mohanty S, Aronson N,

Medley K, Hardison WG. In HCV Naïve Patients: Combination Therapy Improves Viral Clearance When Compared to Induction Therapy. Gastroenterology 1999;116:L0172.

69. Hassanein T, Behling C, Monson P, Chatfield E, Taha H, Mohanty S, Aronson N,

Hardison WG. Histology of Chronic HCV Based on Genotype. Gastroenterology 1999;116:L0173.

70. Hassanein T, Behling C, Monson P, Chatfield E, Taha H, Mohanty S, Aronson N, Hardison WG. Fibrosis Score and Platelet Level in Patients with Chronic HCV. Gastroenterology 1999;116:L0174.

71. Rose S, Pretorius D, Nelson T, Kinney T, Huynh T, Roberts A, Valji K, D'Agostino H,

James G, Orloff M, Hassanein T, Hart M. Adjunctive 3D US Guidance for Achieving Portal Vein Access During Tips Procedure: The Influence of Directional Cues and Procedural Education. Radiology 1998;209:A1097.

72. Koehler G, Hart M, Hassanein T, Martin R, Mehta R. The Presence of Renal

Insufficiency Influences Outcome from Liver Transplantation. J Am Soc Nephrol 1999;10:A146.

73. Mello M, Kono Y, Ferret C, Hassanein T, Hart M, Mattrey R. Contribution of Feridex to

Liver MRI in End Stage Liver Disease. Radiology 1999;213:A311.

74. Mattrey R, Kono Y, Mello M, Hassanein T, Hart M. Contribution of Feridex to Liver MRI in End Stage Liver Disease. Hepatology 1999;30:A469.

75. Kono Y, Mattrey R, Sirlin C, Rose S, Hassanein T. Usefulness of Gray-scale Ultrasound

Contrast Enhancement for Evaluation of TIPS Stenosis. Hepatology 1999;30:A1705.

76. Kono Y, Mattrey R, Rose S, Hassanein T, Hart M. Ultrasound Contrast Gray-scale Enhancement to Detect Residual Liver Tumor or Recurrence After Ablation or Chemoembolization. Hepatology 1999;30:A2086.

77. Chen P, Mohanty S, Hwang S, Chatfield, E, Monson P, Aronson N, Hassanein T.

Lamivudine Treatment in Cholestatic Acute Hepatitis B. AJG 1999;94:A310.

78. Mohanty S, Chen P, Aronson N, Monson P, Hwang S, Behling C, Masliah E, Hassanein T. Spectrum of Liver Diseases in HIV Infected Patients: A Review of Autopsy Reports. Hepatology 1999;30:A526.

79. Aronson N, Monson P, El-Mokadem H, Mohanty S, Chen P, Chatfield E, Hwang S,

Rosenberg J, Lam V, Behling C, Hassanein T. Outcome and Histological Findings of Liver Biopsies in a Cohort of HIV Infected Patients. Hepatology 1999;30:A519.

80. Hassanein T, Monson P, Behling C, Chatfield E, Aronson N, Chen P, Medley K, Do D,

Hassanein, Tarek

Page 63

Ma M, Hwang S, Hardison WG. In HCV Non-Responders: Combination Therapy is More Effective Than Induction Therapy in Achieving Viral Clearance. Hepatology 1999;30:A1864.

81. Hassanein T, Monson P, Behling C, Chatfield E, Aronson N, Chen P, Medley K, Hwang

S, Do D, Ma M, Hardison WG. In HCV Relapsers: Induction Therapy Does Not Improve Viral Clearance Compared to Combination Therapy. Hepatology 1999;30:A154.

82. Hassanein T, Monson P, Behling C, Chatfield E, Aronson N, Chen P, Hwang S, Hardison

WG. Combination Therapy Results in a Significant Reduction in Transaminase Levels in Patients with Normal Pre-Treatment Transaminase Levels. Hepatology 1999;30:A177.

83. Monson P, Behling C, Chen P, Mohanty S, Chatfield E, Aronson N, Oliver D, Hassanein

T. Virologic and Biochemical Response to Treatment in Patients with Chronic Hepatitis C with Elevated Gamma Glutamyl Transpeptidase. Hepatology 1999;30:A1804.

84. Behling C, Monson P, Chen P, Chatfield E, Aronson N, Oliver D, Hassanein T. Bile Duct

Injury in Patients with Chronic Hepatitis C and Normal or Elevated Gamma Glutamyl Transpeptidase Levels. Hepatology 1999;30:A1803.

85. Martin R, Chatfield E, Albanese L, Hwang S, Hart M, Hassanein T. The evolving Role of

Nursing in Liver Disease Management: Creation of a Liver Management Team. Hepatology 1999;30:A2114.

86. Hassanein T, Aronson N, Behling C, Torriani F, Chatfield E, Chen P, Mathews C.

Disease Severity of HCV Infection in HIV/HCV Coinfected Patients. Gastroenterology 2000;18:A197.

87. Hassanein T, Aronson N, Behling C, Torriani F, Chatfield E, Chen P, Mathews C. The

Role of HAART on HCV Disease Severity in HIV/HCV Coinfection. Gastroenterology 2000;118:A6558.

88. Chen P, Monson P, Behling C, Lam V, Hassanein T. Histological and Virological

Features of HCV Patients With and Without History of Jaundice. Gastroenterology 2000;118:A6495.

89. Chen P, Monson P, Chatfield E, Pozza R, Krinsky M, Hassanein T. In HCV Naïve

Patients: Combination Therapy with Daily Interferon Improves Viral Clearance When Compared to Induction Therapy. Gastroenterology 2000;118:A6493.

90. Chen P, Monson P, Behling C, Chatfield E, Pozza R, Krinsky M, Hassanein T.

Combination Therapy with or without Induction for Non-Responders to Interferon Monotherapy. Gastroenterology 2000;18:A6492.

91. Behling C, Monson P, Pohl A, Aronson N, Chen P, Oliver D, Hassanein T. Bile Duct

Injury, Elevated GGT and Response to Treatment in Non-Cirrhotic Hepatitis C. Gastroenterology 2000;118:A6469.

92. Hilsabeck R, Hassanein T, Perry W. Life and Illness Satisfaction for Patients with

Chronic Hepatitis C. Gastroenterology 2000;118:A6564.

Hassanein, Tarek

Page 64

93. Hilsabeck R, Hassanein T, Perry W. Severity of Depression and Anxiety in Patients with Chronic Hepatitis C. Gastroenterology 2000;118:A6563.

94. Hilsabeck R, Hassanein T, Perry W. Impaired Quality of Life Varies Among Subsamples

of Patients with Chronic Hepatitis C. Gastroenterology 2000;118:A6562.

95. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Liver Transaminase Levels and Platelet Counts as Predictors of Degree of Fibrosis in Chronic Hepatitis C. Gastroenterology 2000;118:A261.

96. Mathews C, Aronson N, Hassanein T. Prevalence of HCV in an HIV cohort at a

University HIV Clinic. Gastroenterology 2000;118:A211.

97. Chen P, Behling C, Monson P, Aronson N, Chatfield E, Hassanein T. Response and Tolerance to Prolonged Induction Interferon α-2a in Naïve Chronic Hepatitis C. Gastroenterology 2000;118:A6494.

98. Di Bisceglie AM, Schwartz M, Reddy R, Martin P, Gores G, Lok A, Gish R, Van Thiel

DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Blei A. Hepatitis C and Hepatocellular Carcinoma in African Americans. Gastroenterology 2000;118:A6514.

99. KonoY, Mattrey RF, Pinnell SP, McKlendin K, Rose S, Hassanein T. Ultrasound

Angiography with intravenous contrast agent using wideband gray-scale harmonic imaging for evaluation of TIPS stenosis. Gastroenterology 2000;118:A990.

100. Kono Y, Mattrey RF, Pinnell SP, Rose S, Hassanein T, Hart M. Characterization of the

Liver Tumors and Evaluation of the Treatment of HCCS with Ultrasound Contrast Enhancement Using Wideband Gray-Scale Harmonic Imaging. Gastroenterology 2000;118:A1067.

101. Hilsabeck R, Perry W, Hassanein T. Severity and Co-Morbidity of Depression and

Anxiety in Patients with Chronic Hepatitis C not Receiving Antiviral Therapy. AJG 2000;95:2513-A348.

- 102. Hilsabeck R, Perry W, Hassanein T. Life and Illness Satisfaction for Patients with

Chronic Hepatitis C. AJG 2000;95:2512-A346.

103. Hilsabeck R, Perry W, Hassanein T. Mood Impairment in HCV Patients with and without a History of Intravenous Drug Use. AJG 2000;95:2512-A347.

104. Monson P, Oliver D, Pohl A, Behling C, Aronson N, Rossetti L, Hassanein T. Factors

Associated with Steatosis in Patients with Chronic Hepatitis C. AJG 2000;95:2517-A361.

105. Hassanein T, Monson P, Behling C, Krinsky M. Combination Therapy Results in a Significant Reduction in Transaminase Levels in Patients with Pre-Treatment Transaminase Levels. AJG 2000;95:2512-A345.

106. Hilsabeck R, Perry W, Hassanein T. Attention and Memory Functioning in Non-Cirrhotic

Patients with Chronic Liver Disease. Hepatology 2000;32:A1650.

107. Hilsabeck R, Hickman S, Boland B, Oliver D, Hart M, Perry W, Hassanein T. Cognitive

Hassanein, Tarek

Page 65

Dysfunction in Patients with and without a History of Hepatic Encephalopathy. Hepatology 2000; 32:A1476.

108. Hilsabeck R, Perry W, Hassanein T. Measures of Fatigue in Patients with Chronic Hepatitis C. Hepatology 2000;32:A1565.

109. Hilsabeck R, Hickman S, Boland B, Oliver D, Hart M, Khanna A, Perry W, Hassanein T.

Degree of Cognitive Impairment in Patients Evaluated for Liver Transplant. Hepatology; 32: A1786.

110. Hilsabeck R, Hickman S, Boland B, Oliver D, Hart M, Khanna A, Perry W, Hassanein T.

Degree of Cognitive Impairment in Patients Evaluated for Liver Transplant. Hepatology; 32: A1786.

111. Kono Y, Mattrey R, Pinnell S, Rose S, Hart M, Hassanein T. Assessment of HCC

Viability After Therapy in Cirrhotic Patients with Contrast-Enhanced Wideband Grayscale Harmonic Imaging. Hepatology 2000;32:A277.

112. Albanese L, Medley K, Pozza R, Peeters R, Wahlstrom E, Hassanein T. Prevalence of

Hepatitis C in Community Based Screening Programs in Southern California. Hepatology 2000;32:A1566.

113. Hassanein T, Oliver D, Monson P, Pohl A, Aronson N, Rossetti L, Krinsky M, Hart M.

Comparison of High Dose Interferon Plus Low Dose Ribavirin to Low Dose Interferon Plus Standard Dose Ribavirin. Hepatology 2000;32:A1647.

114. Oliver D, Monson P, Pohl A, Campbell D, Hassanein T. Interferon, Body Mass Index and

Response to Treatment in Chronic Hepatitis C. Hepatology 2000;32:A1646.

115. Rose S, Kinney T, Stella D, Hart M, Hassanein T, Pretorius D, Nelson T, Levin D, Khanna A. Three-dimensional ultrasound (3D US) for estimation of left lateral segment liver volume for split liver donation. Pediatric Transplantation 2000;4:P66.

116. Rose S, Roberts A, Kinney T, Valji K, Hassanein T, Lavine J, Hart M, Khanna A.

Integral role of interventional radiology in the development of a pediatric liver transplantation program. Pediatric Transplantation 2000;4:P322.

117. Khanna A, Lavine J, Cashman J, Garfinkel M, Hall K, Frankville D, Randle C, Nyhan W,

Wahlstrom E, Hassanein T, Hart M. First year evaluation of new pediatric abdominal transplantation program at a major teaching hospital. Pediatric Transplantation 2000;4:P86.

118. Khanna A, Gutmacher H, Garfinkel M, Cashman J, Hall K, Randall C, Greenburg M,

Frankville D, Dohil R, Shapiro W, Taylor S, Wahlstrom E, Hassanein T, Nyhan W, Lavine J, Hart M. Early enteral feeding obviates the need for parenteral nutrition in pediatric liver transplant (OLTX) patients. Pediatric Transplantation 2000;4:P93.

119. Pilai GR, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. Induction of apotisis in

human lung cancer cells by curcumin. Cancer Letters 2004;Vol 208:163-170.

Hassanein, Tarek

Page 66

120. Khanna A, Lavine J, Hassanein T, Hart M. Setting up pediatric abdominal transplantation program in a managed care environment: preliminary experiences. Pediatric Transplantation 2000;4:P294.

121. Hilsabeck R, Hassanein T, Perry W. Prevalence of Impaired Cognitive Functioning in

Outpatients with Chronic Liver Disease. Archives of Clinical Neuropsychology 2000;15:705.

122. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T. Usefulness of Gray-scale Ultrasound

Contrast Enhancement for Evaluation of TIPS Stenosis. Journal of Ultrasound in Medicine 2000;19:P65

123. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T, Hart M. Evaluation of Tumor

Vascularity-Characterization and Evaluation of the Treatment. Journal of Ultrasound in Medicine 2000;19:P23.

124. Wasserman R, Brau N, Hassanein T, Bini E, Sulkowski M, Dieterich D. Once Weekly

Epoetin Alfa Increases Hemoglobin and Decreases RBV Discontinuation Among HCV Patients Who Develop Anemia on RBV/INF Therapy. Hepatology 2000;32:A833.

125. Khanna A, Lavine J, Hassanein T, Garfinkel M, Hall K, Frankville D, Wahlstrom E, Hart

M. First Year Evaluation of Living Related Liver Transplantation Program at a Major Teaching Hospital. First Congress International Pediatric Transplantation Association, Rome Italy, August 2000.

126. Hart M, Hassanein T, Rose S, Roberts A, Kenny T, Garfinkel M, Wahlstrom E, Lavine J,

Khanna A. Evaluation and Outcome of Living Related Donors for Liver Transplantation. Workshop on Living Donor Liver Transplantation, NIH, December 2000.

127. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T. Ultrasound Contrast Venography of

TIPS – Gray-scale Ultrasound vs X-ray Venography. AIUM 2001.

128. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T, Hart M. Contrast-Enhanced B-mode Harmonic Imaging for the Evaluation of HCC Viability after Therapy in Cirrhotic Patients. AIUM 2001.

129. Oliver D, Hilsabeck R, Rossetti L, Aronson N, Behling C, Hassanein T.Platelet Count as

a Predictor of Fibrosis Stage in HIV/HCV Co-Infected Patients. Gastroenterology 2001;120:A-515.

130. Oliver D, Hilsabeck R, Rossetti L, Barber E, Mathews WC, Hassanein T. The Impact of

HCV on Survival of HIV-Infected Patients. Gastroenterology 2001;120:A-516.

131. Hilsabeck R, Carlson M, Hassanein T, Perry W. Relationship of Depression and Anxiety Symptoms to Disease Severity in Patients with Chronic Hepatitis C. Annals of Behavioral Medicine2001: 23,S038.

Hassanein, Tarek

Page 67

132. Hilsabeck R, Carlson M, Hassanein T, Perry W. Social Support of Patients with Chronic Hepatitis C. Annals of Behavioral Medicine 2001;23:S186.

133. Hilsabeck, RC, Carlson, MD, Perry, W, Hassanein, TI. Comparison of Emotional and

Cognitive Functioning in Patients Pre- and Post- Liver Transplant, American Journal of Transplantation 2001;1:422.

134. Hilsabeck R, Hickman S, Boland B, Williams B, Boyd C, Hassanein T, Perry W. The

pattern of memory deficits in patients with end stage liver disease. Journal of the International Neuropsychological Society 2001;7:169.

135. Hilsabeck R, Hassanein T, Perry W. Attention and Memory Impairment in Noncirrhotic

Patients with Liver Disease. Journal of the International Neuropsychological Society 2001;7:169.

136. Hilsabeck R, Hickman S, Boland B, Williams B, Boyd C, Hassanein T, Perry W.

Neuropsychological Functioning of Patients Evaluated for Liver Transplantation. Journal of the International Neuropsychological Society 2001;7:169.

137. Rose S, Hassanein, T, Easter D, Gamagami R, Bouvet M, Pretorius D, Nelson T, Kinney

T, James G. Value of Three-dimensional US for Optimizing Guidance for Ablating Focal Liver Tumors, JVIR 2001, 12:507.

138. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Sulkowski M. Once-

weekly Recombinant Human Erytopoetin (Epoetin Alfa) Facilitates Optimal Ribavirin (RBV) Dosing in Hepatitis C virus (HCV)-infected Patients Receiving Interferon--2b (IFN)/RBV Combination Therapy, Gastroenterology 2001;120:A-64.

139. Stange J, Mitzner S, Hassanein TI, Mehta R, Bartlett R, Albumin Dialysis as a New Tool

for Extracorporeal Liver Support-Clinical Data from 19 Centers Reporting 103 Patients and Two Prospective Randomized Controlled Trials, Gastroenterology 2001;120:A-542.

140. Thomas JL, Hilsabeck RC, Carlson MD, Hassanein, TI, Perry W. Validation of the Index

of Readiness Scale in Patients with Chronic Hepatitis C, Annals of Behavioral Medicine 2001;23:187(supp).

141. Hilsabeck R, Ziegler B, Carlson M, Rossetti L, Stewart M, Perry W, Hassanein T. Course

of Depression, Anxiety, and Fatigue in HCV Patients on and Off Antiviral Therapy. ACG Scientific Meeting 2001:P114. (Poster)

142. Hilsabeck R, Carlson M, Ziegler B, Medley K, Aronson N, Chatfield E, Perry W,

Hassanein T. Relationship of Chronic HCV Infection, Intravenous Drug Use and Psychiatric History to Depression and Anxiety. ACG Scientific Meeting 2001:P113. (Poster)

143. Hassanein T, Abdeen Om Martin R, Khanna A, Hart M, Mehta R. Octreotide and

Albumin Infusion in the Treatment of Decompensated End Stage Liver Disease and Oliguria. ACG Scientific Meeting 2001: P622. (Oral)

Hassanein, Tarek

Page 68

144. Stange J, Hassanein T. Albumin Dialysis Using the MARS as a Treatment of End Stage Liver Disease and Progressive Cholestasis. ACG Scientific Meeting 2001:P623. (Oral)

145. Khanna A, Hall K, Perry W, Selim K, Hassanein T, Hart M. An Analysis of Causes of

Donor Withdrawal in Adult to Adult Living Related Liver Transplant Program. AASLD 2001. (Poster)

146. Hilsabeck RC, Carlson MD, Ziegler BA, Hassanein TI, Perry W. The Relationship of

Fatigue and Cognitive Functioning in Patients with Chronic Hepatitis C. Archives of Clinical Neuropsychology 2001;16:728.

147. Ziegler BA, Hilsabeck RC, Carlson MD, Hassanein TI, Perry W. Resolution of Cognitive

Impairment after Liver Transplantation: A case study. Archives of Clinical Neuropsychology 2001;16:738.

148. Hassanein T, Aronson N, Oliver D, Barber E, Hilsabeck R, Chatfield E, Stewart M,

Mathews C. Survival in HCV/HIV Co-Infected Patients. Hepatology 2001;34:232A.

149. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo- Estrada R, Vale A, Lok A, Lin A. Treatment With 40 KDA Peginterferon Alfa-2A (PEGASYS) in Combination with Ribavirin Significantly Enhances Quality of Life Compared with Interferon Alfa-2B Plus Ribavirin. Hepatology 2001;34:243A.

150. Khalili M, Hoffman-Terry M, Hassanein T, Bernstein D, Harb G, Pearson D. Safety and

Efficacy of 40 KDA Peginterferon Alfa-2A (PEGASYS) in the Treatment of Patients Co- Infected with HIV and HCV: Preliminary Results from a Randomized Multi-Center Trial. Hepatology 2001;34:328A.

151. Hassanein T, Mehlman L, Barber E, Hall K, El-Tahawy M, Mathews C. Survival of

Patients with Acute Cholestasis. Hepatology 2001;34:524A.

152. Hassanein T, Abdeen O, El-Tahawy M, Hart M, Khanna A, Mehta R. Octreotide, Midodrine and Albumin, Triple Therapy is Effective in Reversing Hepatorenal Syndrome. Hepatology 2001;34:542A.

153. Oliver D, Aronson N, Chargield E, Stewart M, Hilsabeck R, Mathews C, Hassanein T.

Effectiveness of Interferon/Ribavirin Combination Therapy in HIV/HCV Co-Infected Patients. Hepatology 2001;34:584A.

154. Hassanein T, Lyche K, Balan V, Winston D, Rossi S, Rossetti L, Crayne K, Oliver D,

Hilsabeck R. Efficacy of Peg-Intron and Ribavirin in HCV Non-Responders. Hepatology 2001;34:585A.

155. Hassanein T, Hilsabeck R, Carlson M, Hwang S, Medley K, Ziegler B. Assessment of

Quality of Life in Sustained Responders. Hepatology 2001;34:600A.

Hassanein, Tarek

Page 69

156. Hilsabeck R, Carlson M, Cheung G, Ziegler B, Oliver D, Mathews C, Perry W, Hassanein T. Comparison of Psychiatric Symptoms in Patients with Hepatitis C, Human Immunodeficiency Virus and Co-Infection. Hepatology 2001;34:602A.

157. Hassanein T, Barber E, Mehlman L, Hwang S, Costanza C, Mathews C. Comparative

Analysis of Meld Versus Discriminate Function as a Predictor of Patient Mortality in Alcoholic Hepatitis. Hepatology 2001;34:457A.

158. Stange J, Broelsch C, Gerken G, Treichel U, Heemann U, Liebe S, Hassanein T.

Predictably LTX-Costs of Progressive Cholestasis in End Stage Liver Disease can be Reduced by Albumin Dialysis Results of a Prospective Controlled Randomized Trial. Hepatology 2001;34:650A.

159. Hagey L, Stange J, Hassanein T. Removal of Toxic Components of Plasma by the

Molecular Absorbing Recirculating System (MARS) in Patients with Cholestatic Liver Failure. Hepatology 2001;34:661A.

160. Stange J, Hassanein T, Gerken G, Treichel U, Heemann U, Mitzner S. Hepatic

Encephalopathy in End Stage Liver Disease can be Improved by Albumin Dialysis- Results of a Retrospective Analysis and a Prospective Randomized Controlled Trial. Hepatology 2001;34:661A.

161. Stange J, Hassanein T, Hwang S. Albumin Dialysis as a Bridge to Transplant in Chronic

Liver Disease Complicated by Progressive Cholestasis. Hepatology 2001;34:661A.

162. Khanna A, Hall K, Perry W, Selim K, Hassanein T, Hart M. An Analysis of Causes of Donor Withdrawal in an Adult to Adult Living Related Liver Transplant Program. Joint Transplant Meeting of the American Society of Transplant Surgeons and American Society of Transplantation, April-May 2002.

163. Stange J, Hassanein T, Klammt S, Mitzner S, Lock J, Oliver D. Binding Capacity of the

Albumin's Benzodiazepine Binding Site as a New Parameter for Monitoring Clinical Course of Excretory Liver Failure. DDW May 2002: ID 108436. (Poster)

164. Oliver D, Stewart M, Chatfield E, Aronson N, Selim K, Matthew C, Hassanein T.

Efficacy of Interferon Alpha-2b plus Ribavirin Combination Therapy in HIV/HCV Co- infected Patients. DDW May 2002: ID102516. (Poster)

165. Metwally M, Hassanein T, Zein C, Selim K, Oliver D, Behling C, Zein N. A Simple

Non-Invasive Scoring System for Prediction of Severe Hepatic Fibrosis in Chronic HCV Patients Co-Infected with HIV. DDW May 2002: ID 108422. (Poster)

166. Vaquero J, Oliver D, Hassanein T, Stange J, Blei A. Evaluation of Mental State in a

Clinical Trial of M.A.R.S. for Patients with Acute Hepatic Encephalopathy: Comparison of Two Scales. Scientific Meeting May 2002. (Oral)

Hassanein, Tarek

Page 70

167. Khanna A, Lavine A, Precht T, Hassanein T, Hall K, Frankville D, Wahlstrom HE, Hart M. Living Related Pediatric Liver Transplant: Early Experiences. Abdominal Organ Transplantation from Living Donors: State of the Art Meeting, Gubbio Italy, June 2002.

168. Khanna A, Lavine J, Hassanein T, Precht A, Hart M. Setting Up Living Donor Pediatric

Transplant Program. Abdominal Organ Transplantation from Living Donors: State of the Art Meeting, Gubbio Italy, June 2002.

169. Khanna A, Lavine J, Hassanein T, Hart M. Setting up Pediatric Abdominal

Transplantation Program in a Managed Care Environment: Preliminary Experiences. International Liver Transplantation Society, June 2002.

170. Fried M, Shiffman M., Reddy R, Smith C, Marinos G, Gonzales G, Haussinger D., Diago

M., Giampiero C., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J., Hassanein T. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J. Med, September 2002:347:13.

171. Khanna A, Precht AF, Lavine J, Hall K, Brink JA, Hassanein T, Hart M. Living Related

Pediatric Liver Transplant: Early Experiences. 2nd Congress of International Pediatric Transplant Association, Rio de Janiero, April 2003.

172. Khanna A, Hart ME, Precht AF, Brink JA, Lavine J, Hall K, Hassanein T, Nyhan W.

Lateral Segment Liver Transplantation from Adult Donors: A Practical Alternative to Ameliorate metabolic Diseases in Pediatric Patients. 2nd Congress of International Pediatric Transplant Association, Rio de Janiero, April 2003.

173. Hassanein T, Oliver D, Stange J. Management of Post-Graft Dysfunction (PGD) in

Cadaveric and Living-Related Liver Transplantation by Albumin Dialysis (MARS) ITLS June 2003. (Poster)

174. Stange J, Broelsch C, Gerken G, Heemann U, Hassanein T. Reduction of Predictable

LTX Costs in Liver Failure by Pre-conditioning Albumin Dialysis Resulting in Maintaining Kidney Function; Investigators Lead of a Prospective Randomized Trial. ITLS June 2003. (Poster)

175. Stange J, Hassanein T. Predictably LTx-Costs of progressive cholestasis in end stage

liver disease can be reduced by albumin dialysis – results of a prospective controlled randomized trial. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003

176. Hassanein T, Oliver D. Emergency use of Albumin dialysis (MARS) in cirrhotic patients

with progressive hyperbilirubinemia in the US-Allocation system. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003.

177. Stange J, Hassanein T, Oliver D. Bilirubin trend predicts renal failure and death in

cirrhotics with superimposed acute injury on LTX waiting list. Workshop On

Hassanein, Tarek

Page 71

Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003

178. Hassanein T,Oliver D. Hepatic Coma in Post Graft Dysfunction can be resolved by

albumin dialysis (MARS). Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003

179. Tong M, Hassanein T, Van Antwerp W, Olek E, Murphy B. Delivery of Consensus

Interferon by Continuous Infusion for the Treatment of Chronic Hepatitis C: A Pilot Viral Kinetic Study in Nonresponder Patients. AASLD October 2003. (Poster)

180. Stange J, Siekmoller M, Oliver D, Chauhan DP, Hassanein T. Cytochrome P450 Isoform

Dysfunction in Alcoholic Hepatitis Can Be Reversed by Albumin Dialysis (MARS). AASLD October 2003. (Poster)

181. Hassanein T, Hilsabeck R, Marcott T, Carlson M, Perry W. Driving Performance in

Patients with Chronic Liver Disease. AASLD October 2003. (Poster)

182. Hassanein T, Barakat F, Myers W, Carlson M, Chatfield E, Selim K, Behling C. Effect of Peg Interferon Alpha-2B and Ribavirin Dose on the Histologic Changes in Virologic Nonresponders to the Combination of Standard Interferon Alpha-2B and Ribavirin: A Randomized Controlled Study. AASLD October 2003. (Poster)

183. Hassanein T, Hilsabeck R. Hepatitis C and Cognitive Impairment. The HCV Advocate:

Medical Writer’s Circle. August 2003.

184. Hassanein T, Stange J. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized controlled clinical trial, and clinical experience from 19 centers. Artifical Organs, Volume 26, Issue 2.

185. Hassanen T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with

superimposed acute liver injury: Possible impact of albumin dialysis on hospitalization costs. Liver International 2003: 23(suppl 3):61-65.

186. Hassanein T, Zeh N, Rossi S, Hofmann A, Steinbach J, Hagey L, Oliver D, Stange J.

The effect of extracorporeal albumin dialysis on plasma phospholipid fatty acids in patients with end-stage liver disease. Liver International 2003: 23(suppl 3):34-38.

187. Hassanein T, Deiterich D, Wasserman R, Norbert B, Bini E, Bowers P, Sulkowski M.

Once-weekly epoetin alfa improves anemia and facilitates maintenance of Ribavirin dosing in hepatitis C virus-infected patients receiving Ribavirin plus interferon alfa. American Journal of Gastroenterology. November 2003.

188. Hassanein T, Pillai G, Srivastava A, Chuahan D, Carrier E. Induction of apoptosis in

human lung cancer cells by curcumin. Cancer Letters. 2004.

Hassanein, Tarek

Page 72

189. Hassanein T, Kinney T, Ferrara S, Miller F, Roberts A. Transjugular intrahepatic portosystemic shunt creation as treatment for refractory chylous ascites and chylothorax in patients with cirrhosis. Journal of Virology January 2004.

190. Hassanein T, Kono Y, Alton K, Rose S, Mattrey R. Early assessment of treatment

success with contrast-enhanced ultrasound post-transarterial chemoembolization for Hepatocellular carcinoma.

191. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai M, Pastore G, Trejo-

Estrada R, Vale A, Wintfield N, Green J. The impact of peginterferon alfa 2a plus Ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology 40 (2004)675-681.

192. Stange J, Hassanein T. Predictably LTx-Costs of progressive cholestasis in end stage

liver disease can be reduced by albumin dialysis – results of a prospective controlled randomized trial. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany June 2003.

193. Hassanein T, Oliver D. Emergency use of Albumin dialysis (MARS) in cirrhotic patients

with progressive hyperbilirubinemia in the US-Allocation system. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003.

194. Stange J, Hassanein T, Oliver D. Bilirubin trend predicts renal failure and death in

cirrhotics with superimposed acute injury on LTX waiting list. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003.

195. Hassanein T, Oliver D. Hepatic Coma in Post Graft Dysfunction can be Resolved by

Albumin Dialysis (MARS). Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003.

196. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok Ash,

Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS, Liver Cancer Network. Hepatitis C-related hepatocellulor carcinoma in the United States: influence of ethnic status. Am J Gastorenterol 2003; Sept;98(9):2060.

197. Hassanein T, Barakat F, Myers W, Carlson M, Chatfield E, Selim K, Behling C. (2003)

Effect of Peg Interferon alpha-2b and Ribavirin dose on the histological changes in virologic non-responders to the combination of standard Interferon Alpha-2b and Ribavirin: A randomized controlled study. Hepatology 38(2) Supple 1:742A.

198. Hassanein T,Barakat F, Behling C, Myers W, Carlson M, Chatfield E, Selim K (2003).

Effects of the Combination of Peg-Interferon Alpha-2b and Ribavirin on the inflammation and fibrosis scores of patients with chronic Hepatitis C infection who were virologic non-responders to Interferon Alpha-2b and Ribavirin. The American Journal of Gastroenterology 98, (9), S103

Hassanein, Tarek

Page 73

199. Hassanein T,Barakat F, Behling C, Myers W, Carlson M, Chatfield E, Selim K. Effects of the combination of Peg-Interferon alpha-2b and Ribavirin on the inflammation and fibrosis scores of patients with chronic hepatitis C infection who were virologic nonresponders to Interferon Alpha-2b and Ribavirin. 10/2003 68th Annual Meeting for the American College of Gastroenterology (ACG), Baltimore, MD, Poster Presentation.

200. Lynch P, Hassanein T, Hilsabeck R, Stange J, Blei A. Grading Hepatic Encephalopathy

in a Controlled Trial of MARS. Performance of Two Scales. Hepatology 2004;34:508A.

201. Carlson M, Barakat F, Richards L, Verbeck M, Edwards K, Quach D, Alpert E, Kravetz D, Hassanein T. Sleep and Fatigue in Patients with Chronic Hepatitis C. Hepatology 2004;34:248A.

202. Aguirre D, Sirlin C, Alpert E, Behling C, Mattrey R, Hassanein T. Accurate Non-

Invasive Diagnosis of Liver Fibrosis Using MR Imaging. Hepatology 2004;34:707A.

203. Hassanein T, Tofteng F, Brown R, McGuire B, Lynch P, Mehta R, Larsen F, Gornbein J, Stange J, Blei A. Efficacy of Albumin Dialysis (MARS) in Patients with Cirrhosis and Advanced Grades of hepatic Encephalopthy: A Prosective Controlled, Randomized Multicenter Trial. Hepatology 2004;40:726A

204. Carlson M, Barakat F, Richards L, Verbeck M, Edwards K, Quach D, Alpert E, Kravetz

D, Hassanein T. Sleep and fatigue in patients with chronic hepatitis C. 10/2004 55thAnnual Meeting for the American Association for the Study of Liver disease (AASLD), Boston, MA. Oral Presentation.

205. Lynch P, Hassanein T, Hilsabeck R, Stange J, Blei A. Grading Hepatic Encephalopathy

in a Controlled Trial of Mars: Performance of Two Scales. AASLD, November 2004. (Poster)

206. Kono Y, Alton K, Rose S, Hassanein T, Mattrey R. The Ability of Contrast-Enhanced

Ultrasound (CEUS) to Predict Final Outcome within 1 week after Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC). AASLD, November 2004. (Poster)


D, Hassanein T. Sleep and Fatigue in Patients with Chronic Hepatitis C. AASLD, November 2004.

208. Hassanein T, Tofteng F, Brown R, McGuire B, Lynch P, Mehta R, Larsen F, Gornbein J,

Stange J, Blei A. Efficacy of Albumin Dialysis (MARS) in Patients with Cirrhosis and Advanced Grades of Hepatic Encephalopathy: A Prospective Controlled Randomized Multicenter Trial. AASLD, November 2004. (Oral)

209. Pozza R, Biando K, Maisey A, Hassanein T. Interferon Response Rates in HCV Infected

Patients Awaiting Renal Transplantation, Therapies for Viral Hepatitis, November 2004. (Oral/Poster)

Hassanein, Tarek

Page 74

210. Puckett J, Liu J, Bhalla V, Kravetz D, Krinsky M, Hassanein T, Mittal R. Ultrasound System to Measure Esophageal Varix Pressure: An In-Vitro Validation Study. Am J Physiol Gastrointest Liver Physiol. 2004 Dec 10.1152.


D, Hassanein T. (2004). Sleep and fatigue in patients with chronic hepatitis C. Hepatology 40 (4) Suppl 1:248A.

212. Zarski J, Smith C, Fried M, Hadziyannis S, Rakela J, Hassanein T, Lee S, Wright T. Are

there differences in baseline characteristics or treatment outcomes with Peginterferon alfa-2a (40KD) and Ribavirin in patients infected with HCV Gentotype 1a or 1b? European Association for the Study of Liver Diseaes (EASL), April 2005.

213. Fredrick RT, Hassanein TI. Role of Growth Factors in the Treatment of Patients with

HIV/HCV Coinfection and Patients with Recurrent Hepatitis C Following Liver Transplantation. J Clin Gastroenterol. 2005 Jan:39(1).

214. Stange J, Steiner C, Steffen R, Mitzner R, Oliver DL, Hassanein TI, MARS Registry

Group. Bridging To Liver Transplant with Albumin Dialysis-Annual Report of the International MARS Registry 2004. Am J Gastorenterol 2005; May(5):202.

215. Mokadem H, Salotti J, Richards L, Barakat E, Rose S, Behling C, Sirlin C, Alpert E,

Mattrey R, Khanna A, Hart M, Hassanein T. Effect of Transarterial Chemoembolization (TACE) on Hepatocellular Carcinoma (HCC) Recurrence after Liver Transplantation: A Single Center Experience. Gastroenterology 2005;128(4 Suppl): A757.

216. Ilyas J, Oliver D, Barber E, Verbeck M, Richards L, Carlson M, Barakat F, Hassanein T.

Factors that influence treatment of HIV/HCV co-infected patients. 5/2005 Digestive Disease Week (DDW). Poster Presentation.

217. Yen TY, Khanna A, Valji K, Hart M, Hassanein T. Posthepatic Portal Hypertension

After a Domino Liver Transplantation Due to Pseudo-Budd Chiari Syndrome. Am J Gastorenterol. September 2005, Volume 100(9), pp S196, Abstract #517.

218. Barakat F, Carlson M, Oliver D, Barber E, Travasso J, Verbeck M, Richards L, Alpert E,

Perry W, Hassanein T Pegylated Interferon and Ribavirin Combination Therapy in Patients with Psychiatric Illnesses. Hepatology 2005; 42(4 Suppl 1): 677A.

219. Shahatto L, Pozza R, Hefner A, Biando K, El-Kabany M, Hassanein T. Can HIV-HCV

Coinfection be Effectively Treated in Community Based Clinics? 57thAnnual Meeting of the American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation / Press Release.

220. Kased N, Kwan S, Aguirre D, Santosa A, Wolfson T, Gamst A, Hanna F, Hassanein

T,Sirlin C. Improved Diagnostic and Staging Accuracy for Hepatocellular Carcinoma in Cirrhotic Patients by Combing Superparamagnetic Iron Oxide-enhanced and Multi-phasic Gadolinimum-enhanced Magnetic Resonance Imaging. 57thAnnual Meeting of the

Hassanein, Tarek

Page 75

American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation.

221. Kono Y, Sirlin C, Santillan C, Hughes F, Wolfson T, Alpert E, Mattrey R, Hassanein T.

Non-invasive Assessment of Reticuloendothelial Function using Spio Enhanced MR allows Differentiation of Malignant versus Benign Focal Hypervascular Lesions in End Stage Liver Disease. 57thAnnual Meeting of the American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation.

222. Barakat F, Carlson M, Oliver D, Edwards K, Karlen N, Hilsabeck R, Perry W, Hassanein

T. Fatigue in Patients with Hepatitis C and Non-viral Chronic Liver Disease. Hepatology 2006; 44(4 Suppl 1): 319A.

223. Hassanein T, Oliver D, Carlson M, Barakat F, Mooney S, Stange J. Restoration of

Neurocognitive Functions in Patients Recovering from Severe Grades of Hepatic Encephalopathy Managed by Extracorporeal Albumin Dialysis and/or Standard Medical Therapy in a Randomized Controlled Trial. Hepatology 2006; 44(4 Suppl 1): 363A.

224. Mooney S, Oliver D, Barakat F, Carlson M, Hilsabeck R, Perry W, Hassanein T.

Anxiety and Depressive Symptoms in Patients with Resolving Hepatic Encephalopathy. Hepatology 2006; 44 (4 Suppl 1): 468A.

225. Bacon B, Regev A, Ghalib R, Morelli G, Rothstein K, Hassanein T, Shiffman M, Murphy

B. Use of Daily Interferon Alfacon-1 (Infergen-CIFN) plus Ribavirin (RBV) in Patients Infected with Hepatitis C (HCV) who are Nonrespnders to Previous Pegylated Interferon Plus RBV Therapy: 24-week Data from the Direct Trial. 57thAnnual Meeting of the American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation.

226. Mooney S, Barakat F, Carlson M, Oliver D, Hilsabeck R, Perry W, Alpert E, Hassanein

T. Comparison of Two Assessment Methods for Grading Hepatic Encephalopathy. Gastroenterology 2006; 130(4 Suppl): A809.

227. Amer MO, Richards LM, Barakat F, Kono Y, Rose S, Hart M, Alpert E, Hassanein T.

Impact of Transarterial Chemoembolization on the Outcome of Hepatocellular Carcinoma. Gastroenterology 2007; 132(2 Suppl): A202.

228. Amer M, Youssri M, Barakat F, Naga Y, Kono Y, Richards LM, Alpert E, Sirlin CB,

Rose S, Hart M, Khanna A, Hassanein T. Pretransplant Chemoembolization for Hepatocellular Carcinoma <= 3 cm Dose Not Influence the Outcome after Liver Transplantation. Hepatology 2007; 46(4 Suppl 1): 618A.

229. Bacon B, Regev A, Ghalib R, Morelli G, Rothstein K, Shiffman M, Hassanein T,

Hammond J. The Direct Trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): Treatment of Non-Responders to Previous Pegylated Interferon plus Ribavirin Sustained Virologic Response Data. Hepatology 2007; 46(4 Suppl 1): 311A.

Hassanein, Tarek

Page 76

230. Oliver D, Barakat F, Carlson M, Perry W, Stange J, Hassanein T. Patients with Severe Hepatic Encephalopathy have Different Patterns of Recovery of Neurocognitive Dysfunctions. Hepatology 2007 46(4 Suppl 1): 860A.

231. Hassanein T, Ghalib R, Zein N, Rothstein K, Joshi S, Kwo P, Hammond J. Analysis of

Relapse Rates in Pegylated Interferon and Ribavirin Non-Responders Treated with Daily Concensus Interferon and Ribavirin. Hepatology 2007; 46(4 Suppl 1): 824A.

232. “Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon

alfa-2a or Peginterferon alfa-2b plus Ribavirin”, European Association for the Study of Liver Diseases (EASL), Milan Italy, April 2008. (Poster Presentation).

233. “Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon

alfa-2a or Peginterferon alfa-2b plus Ribavirin”, Digestive Disease Week (DDW), San Diego CA, May 2008. (Poster Presentation).

234. “Factors Contributing to the Low Rate of HCV Evaluation in HIV/HCV Co-infected

Cohort”, Digestive Disease Week (DDW), San Diego CA, May 2008. (Poster Presentation).

235. “Difference in Presentation in Hepatocellular Carcinoma in Egyptian and US Cohorts”,

Digestive Disease Week (DDW), San Diego CA, May 2008. (Poster Presentation).

236. “Extent of Recovery of Neurocognitive Dysfunction in Patients Presenting with Severe Hepatic Encephalopathy”, Digestive Disease Week (DDW), San Diego CA, May 2008. (Oral Presentation).

237. Ribavirin Loading Before Starting Pegylated Interferon Therapy: Effect on RVR and

EVR. (Poster Presentation).

238. Characterization of Lipids in Human Liver Biopsies of Patients with Severe Steatosis (NAFLD) using Mass Spectrometry. (Poster Presentation).

239. Extent of Recovery in Neurocognitive Functions after Liver Transplant in Patients

Presenting with Severe Hepatic Encephalopathy. (Poster Presentation).

240. Neurocognitive Changes in CHC patients: the Effect of Interferon Therapy. (Poster Presentation).

241. Management of Chronic Hepatitis C Patients with Schizophrenia: Should we treat?

(Poster Presentation).

242. Ibrahim A, Ahmed W, Lahsaei S, Hassanein T, DeMaria A. Diastolic Dysfunction in Cirrhosis: Does it Really Exist?

243. Safety and efficacy of pegylated interferon lambda (peg-lambda) compared to pegylated

inferferon (peg-alfa) in HCV-infected patients (G1 2/3) with compensated cirrhosis:

Hassanein, Tarek

Page 77

EMERGE Phase IIB efficacy and safety results through Week 12. AASLD, San Francisco CA, November 2011. (Poster Presentation).

244. The relationship between liver disease indices, cognitive functioning and driving ability

in chronic HCV infection. AASLD, San Francisco CA, November 2011. (Poster Presentation).

245. Baseline predictors for safety-related dose reductions or treatment discontinuations

among patients treated with peginterferon alfa-2a plus ribavirin and their impact on early treatment responses: Interim analysis from Guard-C. AASLD, San Francisco CA, November 2011. (Poster Presentation).

246. Sustained virologic response in American naïve mono-infected chronic hepatitis C

patients treatment with peginterferon alfa plus ribavirin: Final analysis of the large, multinational real-world PROPHESYS database. AASLD, San Francisco CA, November 2011. (Poster Presentation).

247. Effects of ribavirin priming in HCV/HIV co-infected patients in tolerability and outcome.

AASLD, San Francisco CA, November 2011. (Poster Presentation).

248. Psycho-social predictors of medical adherence in HCV patients. AASLD, San Francisco CA, November 2011. (Poster Presentation).

249. A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate

the safety and pharmacokinetics of OCR-002 in patients with stable hepatic cirrhosis. AASLD, San Francisco CA, November 2011. (Poster Presentation).

250. PAGN production as an alternative nitrogen scavenging pathway using OCR-002 in

cirrhotic patients: Potential for additional renal metabolism. AASLD, San Francisco CA, November 2011. (Poster Presentation).

251. Once-daily PSI-7977 plus Peg/RBV in treatment-naïve patients with HCV GT1: Robust

end of treatment response rates are sustained post-treatment. AASLD, San Francisco CA, November 2011. (Poster Presentation).

252. Hassanein T, Nelson D, Lawitz E, et al. PSI-7977 with PEG/RBV elicits rapid declines

in HCV RNA in patients with HCV GT-4 and GT-6. HEPDart, Koloa HI, December 2011. (Poster Presentation)

253. Terrault N, Hassanein T, Joshi S, Lake J, Sher L, Vargas H, McIntosh J, Tang S, Jenkins

T. Once-daily oral avatrombopag (E5501) prior to elective surgical or diagnostic procedures in patients with chronic liver disease and thrombocytopenia: results from a Phase 2, randomized, double-blind, placebo-controlled study (Study 202). AASLD, Boston, MA, November 2012.

254. Hassanein T, Lawitz E, Crespo I, Davis M, DeMicco M, Nelson D, Bernstein D, Afdhal

N, Jacobson I, Vierling J, Gordon S, Anderson J, Hyland R, Hinds R, Symonds W, Albanis E, Arora S, Kowdley K. Once Daily Sofosbuvir (GS-7977) plus PEG/RBV:

Hassanein, Tarek

Page 78

High early response rates are maintained during post-treatment follow-up in treatment- naïve patients with HCV genotype 1, 4, and 6 infection in the Atomic Study. AASLD, Boston, MA, November 2012. (Oral Presentation)

255. Hefner A, Heinlein C, Monson P, Pozza R, Biando K, Reshamwala P, Hassanein T.

Facilitating lifestyle changes to manage progressive fatty liver disease. AASLD, Boston, MA, November 2012. (Oral Presentation)

256. Hassanein T, Tamsen M, Petcharaporn L, Hassanein R, Monson P, Barakat F, Biando K,

Videen J. Extracorporeal Albumin Dialysis improves survival in patients with severe alcoholic hepatitis. AASLD, Boston, MA, November 2012. (Poster Presentation)

257. Everson GT, Sims KK, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M,

Hawkins T, Schwartz H, Rustgi V, Hinestrosa F, Levin JM, Younossi Z, Webster L, Eley T, Huang S-P, McPhee F, Grasela DM, Gardiner DF. Phase 2b study of the interferon- free and ribavirin-free combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection. AASLD, Boston, MA, November 2013. (Oral Presentation)

258. Sulkowski MS, Gardiner DR, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I,

Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind- Rotolo M, Huang S-P, Gao M, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. High rate of sustained virologic response with the all-oral combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV G1, 2, or 3. AALD, Boston MA, November 2013. (Oral Presentation).

259. Hassanein T, Box T, Tong M, Pozza R, Rossaro L, Glenn J, Cheung R, Hemaidan A, He

Y, Sheng Y, Barakat F, Behling C, Liu C, Liu P, Vierling J. Safety, tolerability and efficacy of Fuzheng Huayu in the treatment of liver fibrosis in HCV patients: Results from a Phase 2, randomized, double-blind, placebo-controlled, multicenter study (S- USIIT-01). HEPDart, Big Island, HI, December 2013. (Poster Presentation)

260. Hassanein T, Box TD, Tong MJ, Pozza R, Rossaro L, Glenn JS, Cheung R, Hemaidan A,

He Y, Sheng Y, Barakat F, Behling C, Liu C, Liu P, Vierling JM. A Phase II, randomized, placebo-controlled, double-blind, multi-center study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis. Asian Pacific Association for the Study of the Liver (APASL), Brisbane AU, March 2014.

261. Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Asthappan J, Le

Pogam S, Najera I, Eng S, Zhao S, Brennan B, Voulgaria A, Scalori A. High rates of SVR24 in G1/4 patients with compensated cirrhosis, treated with a triple regimen of danoprevir/r+PegIFNalfa-2a/RBV (treatment naïve), or with a quad regimen of danoprevir/r+mericitabine+PegINFalfa-2a/RBV (previous null responders to PegIFN/RBV). Asian Pacific Association for the Study of the Liver (APASL), Brisbane AU, March 2014.

Hassanein, Tarek

Page 79

262. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. All-oral therapy with Daclatasvir in combination with Asunaprevir and BMS-791325 for treatment-naïve patients with chronic HCV genotype 4 infection. European Association for the Study of the Liver (EASL), London UK, April 2014. (Poster Presentation).

263. Hezode C, Marcellin P, Pol S, Hassanein T, Fleischer-Stepniewska K, Bayka T, Wang T,

Lovell SS, Pilot-Matias T, Vilchez RA. Results from the phase 2 Pearl-I study: Interferon-free regimens of ABT-450/r + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. European Association for the Study of the Liver (EASL), London UK, April 2014. (Poster Presentation).

264. Zeuzem S, Jacobson IM, Bayka T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS,

Wedemeyer H, Tam E, Desmond P, Jensen DM, DiBisceglie AM, Varunok P, Hassanein T, Xiong JJ, DaSilva-Tillmann, B, Larsen L, Podsadecki T. Sapphire-II: Phase 3 placebo-controlled study of interferon-free, 12-week regimen of ABT-450/r/ABT-267, ABT-333, and ribavirin in 394 treatment-experienced adults with Hepatitis C virus genotype 1. European Association for the Study of the Liver (EASL), London UK, April 2014. (Poster Presentation)

265. Hassanein T, Box TD, Tong MJ, Pozza R, Rossaro L, Glenn J, Chueng RC, Hemaidan A,

He Y, Shen Y, Barakat F, Behling C, Liu C, Liu P, Vierling JM. A Phase II, randomized placebo-controlled, double-blind, multi-center study to assess the antifibrotic activity of Fuzheng Huayu in chronic Hepatitis C patients with hepatic fibrosis (S-USIIT-01). Digestive Disease Week (DDW), Chicago, IL, May 2014. (Poster Presentation)

266. Asselah T, Jensen DM, Foster G, Sulkowski M, Ouzan D, Morano L, Buynak R, Agarwal

K, Hassanein T, Forton D, Negro F, Genne D, Kaita K, Maieron A, Preotescu L, Sarrazin C, Zehnter E, Romero-Gomez M, Stern JO, Quinson A, Drulak M, Garcia Jr., M, Voss F, Bocher W, Ferenci P. Faldeprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype-1, treatment- naïve patients: Pooled analysis of Phase III studies. Digestive Disease Week (DDW), Chicago, IL, May 2014. (Poster Presentation)

267. Jensen DM, Foster G, Ferenci P, Cooper C, Dieterich DT, Sulkowski M, Mantry PS,

Buynak R, Hassanein T, Lee WM, Wright D, Tam E, Kaita K, Feinman SV, Scherer J, Olson S, Quinson A. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic Hepatitis C genotype-1 infection: A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (Startversion1&2). Digestive Disease Week (DDW), Chicago, IL, May 2014. (Poster Presentation)

268. Asselah T, Jensen DM, Foster G, Sulkowski M, Ouzan D, Morano L, Buynak R, Agarwal

K, Hassanein T, Forton D, Cho M, Genne D, Kaita K, Maieron A, Preotescu L, Sarrazin C, ehnter E, Streinu-Cercel A, Stern JO, Datsenko Y, Drulak M, Voss F, Quinson A, Ferenci P. Virological response in treatment-naïve patients with chronic HCV genotype- 1 infection receiving Fadaprevir plus pegylated interferon alfa-2a and ribavirin is

Hassanein, Tarek

Page 80

unaffected by ribavirin dose reduction. Digestive Disease Week (DDW), Chicago, IL, May 2014. (Poster Presentation)

269. Bernstein D, Lalezari J, Luo Y, Box TD, Younes ZH, Green S, Bhandari BR, Sepe T,

Cooper C, Tam E, Tsai N, Hassanein T, Xie W, Podsadecki T. Pearl-IV: A 12-week regimen of ABT-450/r/ABT-267 and ABT-333, with or without Ribavirin achieves Svr12 rates ≥90% in treatment-naïve adults infected with Hepatitis C virus genotype 1A. Digestive Disease Week (DDW), Chicago IL, May 2014. (Poster Presentation)

270. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi

Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. All-oral therapy with Daclatasvir in combination with Asunaprevir and BMS-791325 for treatment-naïve patients with chronic HCV genotype 4 infection. Digestive Disease Week (DDW), Chicago IL, May 2014. (Oral Presentation).

271. Feld JJ, Weiland O, Marinho RT, Wedemeyer H, Jacobson I, Jensen DM, Hassanein T,

DeLedinghen V, Diago M, Magenta L, DeKnegt RJ, Ziong, JJ, Coakley E, Baykal T, Tatsch F, Foster GR. ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin achieves high sustained virologic response rates regardless of baseline characteristics: pooled analysis of the SAPPHIRE-I and SAPPHIRE-II studies. ID Week, Philadelphia PA, October 2014. (Poster Presentation).

272. Daclatasvir in Combination with Peginterferon Alfa-2a and Ribavirin for treatment-naïve

patients with HCV Genotype 4 infection: Phase 3 COMMAND-4 results. ID Week, Philadelphia PA, October 2014. (Poster Presentation).

273. Nelson DR, Reddy K, DiBisceglie AM, Ferenci P, Crawford DH, Stauber RE, Yakovlev

AA, Botkin SP, deLedinghen V, Hinrichsen H, Bernstein D, de Knegt RJ, Hassanein T, Norris S, Ziong JJ, McCovern BH, Agarwal K. American Association for the Study of the Liver (AASLD). Boston MA, November 2014. (Poster Presentation).

274. Hefner A, Hill C, Reshamwala P, Hassanein T. Characteristics of nutritional intake in

end-stage liver disease secondary to viral hepatitis, NASH, and alcoholic liver disease. American Association for the Study of the Liver (AASLD). Boston MA, November 2014. (Poster Presentation).

275. Everson GT, Sims KD, Luo W, Gardiner DF, Thuluvath PJ, Schwartz H, Hassanein T,

Lawitz E, Webster LR, Brau N, Desta T, Galati JS, Ghalib RH, Gitlin N, Han S, Hinestrosa F, Rodriguez-Torres M, Nahass R, Ruane PJ, McPhee F. Daclatasvir in combination with asunaprevir and BMS-791325 for prior null responders with chronic HCV genotype 1 infection. American Association for the Study of the Liver (AASLD). Boston MA, November 2014. (Poster Presentation).

276. Pol S, Reddy K, Baykal T, Hall C, Collins C, Vilchez RA, Hezode C, Hassanein T,

Marcellin P, Berenguer M, Fleischer-Stepniewska KM. Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4

Hassanein, Tarek

Page 81

Infection: PEARL-I Study Results. American Association for the Study of the Liver (AASLD). Boston MA, November 2014. (Poster Presentation).

277. Flamm SL, Gane EJ, DuFour JJ, Rustgi V, Bain VG, Crawford DH, Andreone P,

Hassanein T, Mazur WW, Lovell SS, Da Silva-Tillmann B, Shulman N, Puoti M, Box TD. Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients ≥65 Years of Age: Results From Phase 2 and 3 Trials. American Association for the Study of the Liver (AASLD). Boston MA, November 2014. (Poster Presentation).

278. Fortune BE, Garcia-Tsao G, Lim, JK, Groszmann JK, Ciarleglio M, Deng Y, Fallon MB,

Sigal S, Chalasani NP, Reuben A, Vargas HE, Abrams G, Bishop M, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND. The Child- Turcotte-Pugh (CTP) score is best at predicting 6-week mortality in patients with acute variceal hemorrhage (AVH): Analysis of a U.S. Multi-Center Prospective Study. American Association for the Study of the Liver (AASLD). Boston MA, November 2014. (Poster Presentation).

279. Suliman I, Pozza R, Kady Y, Hill C, Couturier TA, Reshamwala P, Hassanein T. The

Combination of Simeprevir and Sofosbuvir for the Treatment of HCV Infection in Patients Post Liver Transplant With Significant Fibrosis. American Association for the Study of the Liver (AASLD). Boston MA, November 2014. (Poster Presentation).

280. Hassanein T, Esshaki Y, Hill C, Pozza R, Higham J, Luvisa BK, Hefner AM.

Daclatasvir Plus Sofosbuvir Plus Ribavirin in HCV Genotype 3 Infected Patients with Cirrhosis Child A: A Randomized Trial for 16 or 24 Weeks. American Association for the Study of the Liver (AASLD). Boston MA, November 2016. (Poster Presentation).

281. Hassanein TI, Castrejon JD, Hefner AM, Soto C, Hill C, Vawter B, Pozza R, Barakat

F, Gutierrez JA. Should Screening for Fatty Liver be Conducted at Primary Care Clinics? American Association for the Study of the Liver (AASLD). Washington DC, October 2017. (Oral Presentation).

Date post:	24-Sep-2020
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

Tarek I. Hassanein, M.D. · Page 1 . CURRICULUM VITAE . Tarek I. Hassanein, M.D. . Business...

Documents